Precocious Puberty
Precocious puberty is the onset of secondary sexual characteristics before age 8 in girls or age 9 in boys, resulting from early activation of the hypothalamic-pituitary-gonadal axis (central) or peripheral sex steroid exposure (peripheral).
Precocious Puberty in Paediatrics
Precocious puberty (PP) is defined as the onset of secondary sexual characteristics before the age of 8 years in girls and before the age of 9 years in boys [1][2].
"Precocious" derives from Latin praecox ("ripening early," from prae- = before + coquere = to cook/ripen). The term literally means "early ripening" — puberty arriving before its expected time.
High Yield – Defining Precocious Puberty
The Pediatric Endocrine Society (formerly LWPES) recommended lowering the age cutoff for precocious puberty to < 7 years in white girls and < 6 years in black girls. Pubertal onset occurring between 7–8 years in white girls and 6–8 years in black girls should be evaluated if there is: [1]
- Unusually rapid pubertal progression resulting in bone age advancement by > 2 years and a predicted height < 150 cm or 2 SDs below genetic target height
- Signs and symptoms of a CNS lesion
- Behaviour-based factors suggesting a child's emotional state is adversely affected by early puberty and potential early menses
For HKU exam purposes, the traditional cutoffs of < 8 years (girls) and < 9 years (boys) remain the standard working definition unless otherwise specified [1][2].
The key clinical concern is twofold:
- Accelerated skeletal maturation → premature epiphyseal fusion → compromised final adult height
- Psychological and social impact on a young child who is physically maturing far ahead of peers
2. Epidemiology and Risk Factors
| Feature | Detail |
|---|---|
| Overall incidence | ~1 in 5,000–10,000 children |
| Sex ratio | F:M ≈ 10:1 for central precocious puberty (CPP) |
| Most common type | Central (gonadotropin-dependent) precocious puberty |
| Most common aetiology in girls | Idiopathic (80% of girls) [2] |
| Most common aetiology in boys | Pathological CNS lesion should always be sought (idiopathic in only ~10% of boys) [2] |
Why the Sex Difference?
Ovaries are very sensitive to pituitary gonadotropin secretion so CPP is fairly common in females. On the contrary, testes are relatively insensitive to gonadotropins, so CPP is uncommon in males, and any underlying CNS pathology should ALWAYS be sought. [2]
| Risk Factor | Mechanism / Explanation |
|---|---|
| Female sex | Ovaries are exquisitely sensitive to even small rises in gonadotropins |
| Born small for gestational age (SGA) | More common in children born SGA — hypothesised due to postnatal catch-up growth with insulin resistance and altered adrenal programming [2] |
| Obesity | Adipose tissue produces leptin (permissive signal for puberty) and aromatase (converts androgens → oestrogens); also associated with insulin resistance which amplifies adrenal androgen secretion |
| CNS insults | Previous irradiation, head trauma, neonatal CNS infections [2] — damage to inhibitory pathways in the hypothalamus can release the "brake" on GnRH pulsatility |
| Exogenous sex steroids / TCM | Drug history: exogenous steroids, Traditional Chinese Medicine (TCM) — some TCM preparations contain phytoestrogens or unlabelled steroids [2] |
| Family history | Genetic susceptibility; familial forms exist (e.g., gain-of-function mutations in KISS1R/KISS1, MKRN3 loss-of-function mutations — the most common genetic cause of familial CPP) |
| International adoption | Children adopted from developing countries to developed countries show increased rates of PP, possibly due to nutritional rehabilitation and environmental endocrine disruptors |
| Ethnicity | Earlier puberty in African-American and Hispanic populations |
| Neurocutaneous syndromes | NF1 (optic pathway glioma → CPP), McCune-Albright syndrome (PPP from autonomous ovarian function) |
3. Anatomy and Physiology of Normal Puberty
Understanding precocious puberty requires understanding normal puberty, because PP is essentially the same process occurring too early.
Normal puberty is initiated when the hypothalamus begins pulsatile secretion of GnRH (gonadotropin-releasing hormone). Before puberty, this is held in check by:
- MKRN3 (makorin ring finger protein 3) — an imprinted gene that suppresses kisspeptin neurons
- GABAergic inhibitory tone — decreases as puberty approaches
- Other inhibitory signals (e.g., neuropeptide Y analogues)
At the appropriate age, these inhibitory influences wane and excitatory signals (kisspeptin, neurokinin B, glutamate) increase → GnRH pulsatility begins → LH and FSH are secreted → gonads produce sex steroids → secondary sexual characteristics develop.
3.2 Normal Pubertal Milestones
Key points from lecture slides: [3]
| Tanner Stage | Feature | Typical Age |
|---|---|---|
| B2 (thelarche) — first sign | Breast bud development | 8–13 y |
| P2 (pubarche) | Pubic hair appearance | 8–14 y |
| Growth spurt | Peak height velocity ~8 cm/year | Early (Tanner 2–3) |
| Menarche | First menstrual period | 10–16 y (mean ~12.5 y); typically Tanner B3–B4, ~2 years after thelarche |
| Adult height | Reached ~2 years after menarche |
| Tanner Stage | Feature | Typical Age |
|---|---|---|
| G2 — first sign | Testicular enlargement ≥ 4 mL (or ≥ 2.5 cm length) | 9–14 y |
| P2 (pubarche) | Pubic hair | 10–15 y |
| Growth spurt | Peak height velocity ~10 cm/year | Late (Tanner 3–4) |
| Voice breaking | Laryngeal cartilage growth | ~13–14 y |
| Adult height | Reached later than girls |
Exam Pearl
The first sign of puberty is:
- Girls: Breast bud (thelarche, B2)
- Boys: Testicular enlargement ≥ 4 mL (G2)
NOT pubic hair — pubic hair (adrenarche) is driven by adrenal androgens and is independent of the HPG axis. This distinction is critical for understanding why isolated premature adrenarche ≠ true precocious puberty.
Assessment using sexual maturity rating of pubertal development (Tanner stage): [4]
- Genital development in males
- Breast development in females
- Pubic hair development in both sexes
| Stage | Girls (Breast) | Boys (Genitalia) | Pubic Hair (Both) |
|---|---|---|---|
| 1 | Prepubertal | Prepubertal testes, penis | None |
| 2 | Breast bud, areolar widening | Testes ≥ 4 mL, scrotal thinning/reddening | Sparse, fine hair at base of penis / labia |
| 3 | Breast enlarges, no contour separation | Penile growth (length), further testicular growth | Darker, curlier, spreading over pubis |
| 4 | Areola forms secondary mound | Penile growth (breadth), glans development, scrotal darkening | Adult-type but limited area |
| 5 | Adult breast contour | Adult genitalia | Adult distribution, spread to medial thighs |
4. Aetiology and Pathophysiology
Key questions to answer: [2]
- Is onset of puberty before 8y (F) or 9y (M)? — ascertain precocious puberty
- Are there any progression of clinical symptoms? — normal variation vs pathological
- Are there any biological/radiological signs of exaggerated maturation?
- Is the PP gonadotropin-dependent or independent? — central vs peripheral PP → if central → idiopathic vs tumour
- Is the predicted adult height affected?
- Are there any psychological consequences?
4.2 Central Precocious Puberty (CPP) — Gonadotropin-Dependent
Central precocious puberty (CPP): premature activation of HPG axis [2]
Pathophysiology: The hypothalamic GnRH pulse generator is activated prematurely → pulsatile GnRH → ↑LH and ↑FSH → gonadal stimulation → sex steroid production → secondary sexual characteristics develop in the normal sequence (consonant/isosexual).
CPP: ↑LH, FSH → ↑oestrogen, testosterone [2]
Because the entire HPG axis is active, the pubertal development is harmonious — it follows the same order as normal puberty, just earlier.
| Category | Examples | Notes |
|---|---|---|
| Idiopathic | Most common overall | 80% in females, only ~10% in males [2] |
| Congenital CNS abnormalities | Hydrocephalus | Disrupts inhibitory neural pathways |
| Acquired CNS insults | Post-irradiation, infection, surgery, head injury | Low-dose cranial irradiation (18–24 Gy) paradoxically causes precocious puberty (damages inhibitory pathways while sparing GnRH neurons); higher doses (> 40 Gy) more likely to cause hypogonadism |
| CNS tumours | Hypothalamic hamartoma (most common tumour cause), optic glioma (especially in NF1), astrocytoma, ependymoma, pineal gland tumours | Hypothalamic hamartomas are ectopic GnRH-secreting neurons — they are benign, non-progressive, and represent the most common identifiable CNS cause of CPP |
| Genetic | MKRN3 loss-of-function (paternally inherited), DLK1 mutations, KISS1/KISS1R gain-of-function | MKRN3 mutations are the most common genetic cause of familial CPP |
Why Hypothalamic Hamartomas Cause CPP
Hypothalamic hamartomas contain ectopic GnRH-producing neurons that fire autonomously, bypassing normal inhibitory regulation. They may also contain astrocytes that release TGF-α and other factors stimulating GnRH secretion. They are not true neoplasms — they do not grow or metastasise. Some are also associated with gelastic (laughing) seizures.
Consequence: normal pubertal development (i.e. consonant) [2]
- Consonant = puberty progresses in the normal sequence (thelarche → pubarche → growth spurt → menarche in girls; testicular enlargement → penile growth → pubarche → growth spurt in boys)
- Isosexual = development appropriate to the child's sex
- Initial growth acceleration (tall for age) → but premature epiphyseal fusion → short final adult height [4]
4.3 Peripheral Precocious Puberty (PPP) — Gonadotropin-Independent
Peripheral precocious (pseudo-)puberty (PPP): gonadal/adrenal sex steroid secretion independent of HPG axis [2]
Pathophysiology: Sex steroids are produced autonomously by the gonads, adrenals, or from exogenous sources, without stimulation by pituitary gonadotropins. Because the HPG axis is not activated, high sex steroid levels actually suppress LH and FSH via negative feedback.
PPP: ↑oestrogen/testosterone → ↓LH, FSH [2]
Consequence: abnormal pubertal development (i.e. dissonant) → can involve isolated ↑androgen/oestrogen or both [2]
Pubertal development may be:
- Isosexual (virilisation in boys, feminisation in girls) — e.g., androgen-secreting tumour in a boy
- Contrasexual/heterosexual (virilisation in girls, feminisation in boys) — e.g., androgen-secreting adrenal tumour in a girl causes virilisation; oestrogen-secreting Sertoli cell tumour in a boy causes gynaecomastia
Key Distinction
Isolated contrasexual development (virilisation in females and feminisation in males) EXCLUDES central precocious puberty (CPP) [4] — because CPP always produces isosexual, consonant development. If you see contrasexual features, think peripheral cause.
| Category | Examples | Pathophysiology |
|---|---|---|
| Adrenal | Adrenal tumour, Congenital Adrenal Hyperplasia (CAH) | CAH (21-hydroxylase deficiency): ↓cortisol → ↑ACTH → adrenal hyperplasia → ↑↑androgen precursors (17-OHP, DHEAS, androstenedione → testosterone). Produces virilisation in both sexes |
| Gonadal | Granulosa cell tumour (ovarian, oestrogen-secreting), Leydig cell tumour (testicular, androgen-secreting), hCG-secreting tumour | hCG is molecularly similar to LH. Any germ cell tumours or hepatoblastoma that produce hCG can activate LH receptors on Leydig cells resulting in ↑testosterone [2] |
| Exogenous sex steroids | Oral contraceptive pills, topical oestrogen/testosterone creams, TCM | Direct exogenous exposure |
| McCune-Albright syndrome | Triad: polyostotic fibrous dysplasia + café-au-lait spots (coast-of-Maine borders) + precocious puberty | Somatic activating mutation in GSNA1 → constitutive activation of Gsα → autonomous cAMP signalling in multiple tissues → autonomous ovarian cyst formation → oestrogen secretion. Predominantly affects girls |
| Familial male-limited precocious puberty (testotoxicosis) | Only in boys | Activating mutation in LH receptor (LHCGR) → constitutive Leydig cell activation → testosterone production without LH stimulation |
| Primary hypothyroidism | See below — important and frequently tested |
Primary hypothyroidism [2]
Pathophysiology: negative feedback → ↑TSH → weak agonising activity at FSH receptor [2]
This is a counterintuitive cause. In severe, longstanding primary hypothyroidism:
- Markedly ↑TRH (trying to stimulate the thyroid)
- ↑TRH stimulates prolactin secretion AND ↑TSH
- TSH has structural homology with FSH (both are glycoprotein hormones sharing the same α-subunit) → at very high levels, TSH can cross-react with and weakly activate FSH receptors (a phenomenon called "specificity spillover" or the "overlap syndrome")
- In girls: ovarian stimulation with isolated breast development [2]
- In boys: isolated testicular enlargement [2] (without virilisation — because FSH stimulates Sertoli cells and seminiferous tubules, not Leydig cells)
Clinical features: delayed bone age with poor growth velocity (∵hypothyroidism) [2]
Exam Pearl — Hypothyroidism and PP
This is the only cause of precocious puberty with DELAYED bone age and poor growth. All other causes of PP cause advanced bone age and initial growth acceleration. This paradox makes it an exam favourite.
Prognosis: excellent with treatment — thyroid hormone replacement reverses the PP [2].
4.4 Normal Variants (Benign / Non-Progressive)
These are isolated, non-progressive forms of early sexual development that do NOT represent true precocious puberty. They are important to recognise to avoid unnecessary investigation and treatment.
- Definition: Isolated breast development in girls, typically < 2 years of age (most common at 6–24 months) with a second peak at 6–8 years
- Pathophysiology: Transient or low-level ovarian activity; may represent residual "mini-puberty" of infancy or increased end-organ sensitivity to low levels of circulating oestrogens
- Key features that distinguish from CPP:
- Breast development is isolated — no pubic hair, no growth acceleration, no advanced bone age
- Breast size may fluctuate (wax and wane)
- No progression to other pubertal signs
- Normal growth velocity
- Bone age = chronological age
- Management: Reassurance and observation. Follow up every 6 months to ensure no progression.
- Caveat: ~10-15% may progress to CPP → monitor
- Definition: Isolated appearance of pubic/axillary hair, body odour, and/or mild acne before 8 years in girls or 9 years in boys
- Pathophysiology: Early maturation of the zona reticularis of the adrenal cortex → increased DHEAS secretion. This is independent of the HPG axis — the adrenal gland is "waking up" early, but the gonad is not.
- Key features:
- No breast development (girls) or testicular enlargement (boys)
- Mildly advanced bone age possible (< 2 years ahead)
- Normal or mildly elevated DHEAS for age (but within early pubertal range)
- Growth velocity normal or mildly increased
- Important: Must rule out CAH (especially non-classical/late-onset 21-hydroxylase deficiency) and androgen-secreting tumours if rapidly progressive or accompanied by clitoromegaly/virilisation
- Long-term associations: ↑risk of PCOS, insulin resistance, metabolic syndrome in later life (especially if born SGA)
Isolated menarche: isolated menstruation in girls < 9 years [2]
Aetiology: unknown [2]
Need to rule out: foreign body, local mass, McCune-Albright syndrome [2]
Clinical features: [2]
- Functional ovarian cyst
- ↑risk of accelerated bone maturation (∵↑oestrogen)
Investigation: LHRH test shows inconsistent response [2]
5. Clinical Features
| Symptom | Pathophysiological Basis |
|---|---|
| Breast development in girls | Oestrogen stimulates mammary gland ductal and stromal proliferation |
| Testicular enlargement / scrotal pigmentation in boys | LH → Leydig cell stimulation → testosterone; FSH → Sertoli cell/seminiferous tubule growth |
| Pubic / axillary hair | Androgens (DHEAS, testosterone) stimulate pilosebaceous unit follicles in androgen-sensitive areas |
| Body odour | Androgens stimulate apocrine sweat glands in axillae and groin |
| Acne | Androgens ↑sebum production via sebaceous gland stimulation → follicular plugging → Cutibacterium acnes proliferation → inflammation [6] |
| Facial hair, voice deepening (boys) | Testosterone → laryngeal cartilage growth and vocal cord thickening; terminal hair growth in androgen-dependent facial follicles |
| Rapid growth / tall for age | Sex steroids → ↑GH and IGF-1 secretion → accelerated linear growth; also direct stimulation of growth plates |
| Vaginal bleeding / menarche | Oestrogen → endometrial proliferation; withdrawal or fluctuating levels → shedding |
| Nocturnal sperm emission (boys) | Testosterone → spermatogenesis maturation [4] |
| Mood changes, aggression, sexual behaviour | Sex steroids affect limbic system; psychosocial impact of physical maturation out of sync with cognitive development |
| Headache, vomiting, visual blurring, visual field defects, seizures | Symptoms of a CNS lesion (tumour/hydrocephalus) causing CPP [4] |
| Symptoms of hypothyroidism | Fatigue, weight gain, constipation, cold intolerance, dry skin — may coexist if 1° hypothyroidism is the cause [4] |
5.2 Signs (What You Find on Examination)
| Sign | Significance / Pathophysiology |
|---|---|
| Height, weight, height velocity (cm/year) [4] | Accelerated growth velocity in PP (except in hypothyroidism-related PP where growth is poor) |
| Plotting on growth chart | Child will be tall for age initially but final height compromised due to premature epiphyseal fusion |
| Tanner staging of secondary sexual characteristics | Quantifies pubertal progress; key to documenting consonant vs dissonant development [2][4] |
| Body habitus / obesity | Obesity is both a risk factor for and a mimic of early puberty (lipomastia can be mistaken for thelarche) |
| Sign | Significance |
|---|---|
| Café-au-lait spots [4] | McCune-Albright syndrome (irregular/"coast-of-Maine" borders, large, unilateral); NF1 (smooth/"coast-of-California" borders, ≥ 6 spots > 5 mm prepubertal) — NF1 associated with optic glioma → CPP |
| Neurocutaneous markers [2] | Ash-leaf spots (tuberous sclerosis), port-wine stain (Sturge-Weber) — associated CNS lesions |
| Acne | Androgen effect |
| Acanthosis nigricans | Insulin resistance (associated with obesity-related early puberty; also seen in McCune-Albright) |
Neurological exam, optic fundi, visual fields for CNS lesion [2]
| Sign | Significance |
|---|---|
| Visual field defects (classically bitemporal hemianopia) | Chiasmal compression by suprasellar mass (craniopharyngioma, pituitary tumour, optic glioma) |
| Papilloedema | Raised intracranial pressure from tumour/hydrocephalus |
| Cranial nerve palsies | CNS tumour effect |
| Scoliosis / body asymmetry [2] | May indicate NF1 or spinal cord/paraspinal tumour |
| Gelastic (laughing) seizures | Pathognomonic of hypothalamic hamartoma |
| Sign | Significance |
|---|---|
| Thyroid examination [2] | Goitre → primary hypothyroidism as cause of PP |
| Abdominal/pelvic mass | Ovarian tumour (granulosa cell tumour), adrenal tumour, hepatoblastoma (hCG-secreting) |
| Testicular examination | Critical in boys — see below |
Ultrasound testis interpretation: [2]
| Finding | Interpretation | Why? |
|---|---|---|
| Bilateral testicular enlargement | CPP (∵↑gonadotropin stimulation) | LH + FSH stimulate both testes symmetrically → bilateral growth |
| Unilateral testicular enlargement | Gonadal tumour (Leydig cell tumour) | Autonomous hormone production from one testis only |
| Prepubertal-sized testes | PPP (∵↓gonadotropin) | Sex steroids are coming from a non-gonadal source (adrenal or exogenous), so gonadotropins are suppressed and testes remain unstimulated |
High Yield Exam Point
Testicular size in boys with PP is the single most important clinical sign for distinguishing CPP from PPP:
- Big testes bilaterally = CPP (HPG axis active)
- Big testis unilaterally = gonadal tumour
- Small (prepubertal) testes = PPP (HPG axis suppressed; androgens from elsewhere)
The exception is familial testotoxicosis (activating LH receptor mutation) where testes may be mildly enlarged bilaterally despite being gonadotropin-independent.
| Feature | Consonant (CPP) | Dissonant (PPP) |
|---|---|---|
| Sequence | Normal pubertal sequence | Abnormal — may skip stages or have contrasexual features |
| Sexual development | Isosexual | May be isosexual or contrasexual |
| Testes (boys) | Enlarged bilaterally | Prepubertal or unilaterally enlarged |
| Growth | Accelerated | Accelerated (except hypothyroidism) |
| Bone age | Advanced | Advanced (except hypothyroidism → delayed) |
Short stature: [4]
- Increased rate of bone maturation results in early closure of epiphyses
- Ultimate height will be less than it would have been
The mechanism:
- Sex steroids (especially oestrogen, which is the final common mediator of epiphyseal fusion in both sexes — testosterone is aromatised to oestrogen at the growth plate)
- → Accelerate growth plate maturation and chondrocyte senescence
- → Premature fusion of the epiphyseal growth plates
- → Loss of remaining growth potential
- → Short final adult height despite being initially tall for age
This is why treatment of CPP aims to suppress the HPG axis and slow skeletal maturation — to preserve growth potential.
Impact on psychological health/wellbeing [2]
- Social isolation from peers (physically different)
- Risk of sexual abuse (appearance of physical maturity in a cognitively immature child)
- Behavioural problems, anxiety, depression
- Body image disturbance
- Behaviour-based factors suggesting a child's emotional state is adversely affected by early puberty and potential early menses [1]
| Feature | CPP | PPP | Normal Variant |
|---|---|---|---|
| HPG axis | Activated | Suppressed | Not activated |
| LH (basal) | ↑ (pubertal, > 0.2 mIU/L) | ↓ (prepubertal, < 0.2 mIU/L) | Prepubertal |
| FSH | ↑ (but less discriminating) | ↓ or normal | Prepubertal |
| Sex steroids | ↑ | ↑ | Normal or mildly ↑ |
| Development | Consonant, isosexual | Dissonant, may be contrasexual | Isolated single feature |
| Bone age | Advanced | Advanced (except hypoT → delayed) | Normal or mildly advanced |
| Growth velocity | Accelerated | Accelerated (except hypoT → poor) | Normal |
| Progression | Progressive | Variable | Non-progressive or slowly progressive |
| Testes (boys) | Bilateral enlargement | Prepubertal or unilateral enlargement | Prepubertal |
High Yield Summary
- Definition: PP = secondary sexual characteristics before 8y (girls) or 9y (boys)
- CPP (gonadotropin-dependent): Premature activation of HPG axis → consonant, isosexual development. Idiopathic in 80% girls; always look for CNS pathology in boys.
- PPP (gonadotropin-independent): Autonomous sex steroid production → dissonant development, may be contrasexual. Causes: adrenal (CAH, tumour), gonadal (granulosa/Leydig cell tumour), hCG-secreting tumour, McCune-Albright, testotoxicosis, exogenous steroids, primary hypothyroidism.
- Normal variants: Premature thelarche, adrenarche, menarche — isolated, non-progressive, benign.
- Primary hypothyroidism is the ONLY cause with delayed bone age and poor growth — TSH cross-reacts with FSH receptors.
- Testicular size in boys is the most important clinical sign: bilateral ↑ = CPP; unilateral ↑ = tumour; prepubertal = PPP.
- Key concern: Premature epiphyseal fusion → compromised final adult height; psychological impact.
- Basal LH > 0.2 mIU/L suggests pubertal (central) activation.
- McCune-Albright syndrome = polyostotic fibrous dysplasia + café-au-lait spots (coast-of-Maine) + precocious puberty (autonomous ovarian cysts).
- hCG-secreting tumours (germ cell tumours, hepatoblastoma) cause PPP in boys because hCG mimics LH at Leydig cell receptors.
Active Recall - Precocious Puberty (Definition to Clinical Features)
[1] Lecture slides: GC 149. Premature puberty puberty and related disorders.pdf (Defining precocious puberty slide) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf (Pages 71–73, Approach to Precocious Puberty) [3] Lecture slides: CFB (PAE02) Child growth and development.pdf [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Page 676, Clinical Manifestation and Diagnosis) [5] Senior notes: Maksim Medicine Notes.pdf (Page 108, McCune-Albright syndrome association) [6] Senior notes: Ryan Ho Rheumatology.pdf (Page 126, Acne Vulgaris pathogenesis)
Differential Diagnosis of Precocious Puberty
When a child presents with early secondary sexual characteristics, the clinician's job is not simply to confirm "this is precocious puberty" — it is to categorise the type, identify the cause, and distinguish true pathology from benign normal variants. The differential diagnosis is therefore structured around three tiers:
- Is this truly precocious puberty, or a benign normal variant?
- If pathological, is it central (gonadotropin-dependent) or peripheral (gonadotropin-independent)?
- Within each category, what is the specific aetiology?
Tier 1: Benign Normal Variants vs Pathological Precocious Puberty
This is the single most important first distinction. Roughly 50–60% of children presenting with early sexual development have a normal variant [2] — only isolated development of one secondary sexual characteristic, with no progression. These do not require treatment but do require follow-up.
| Feature | Benign Normal Variant | Pathological PP |
|---|---|---|
| Number of pubertal signs | Only one 2° sexual characteristic shows premature development (i.e. NOT true PP) [2] | Multiple features progressing |
| Progression | Non-progressive or slowly waxes/wanes | Progresses rapidly with accelerated bone maturation [2] |
| Growth velocity | Normal for age | Accelerated (except hypothyroidism-related PP) |
| Bone age | Normal or mildly advanced (< 2 yr) | Advanced (> 2 yr ahead) |
| LH | Prepubertal | Pubertal in CPP; suppressed in PPP |
| Management | Workup: sought aetiology → monitor and prevent PP [2] | Active investigation and treatment |
Exam Pearl – Don't Over-Investigate Normal Variants
A very common exam mistake is to jump straight to MRI brain for every child with early breast buds. If the child has isolated, non-progressive breast development with normal growth velocity and bone age → this is premature thelarche, not CPP. However, ~10–15% may progress to CPP, so longitudinal follow-up (every 6 months) is essential.
- Classical features include isolated breast development with normal bone age and linear growth velocity for age in the absence of other secondary sexual characteristics [7]
- Two peaks: first two years of life and 6–8 years old, self-limiting, no investigations needed [9]
- Pathophysiology: transient/low-level ovarian follicular activity or end-organ hypersensitivity to low circulating oestrogens; may represent residual "mini-puberty of infancy"
- Why only breast? Because ovarian follicles can transiently secrete small amounts of oestradiol (enough to stimulate breast tissue) without full HPG axis activation
- Must exclude: progression to CPP (follow up), ovarian pathology (if rapid or unilateral)
- Characterised by appearance of pubic or axillary hair (pubarche) prior to age 8 in females and age 9 in males with mild elevation in serum DHEAS for age [7]
- Pathophysiology: early maturation of the adrenal zona reticularis → ↑DHEA/DHEAS production → androgen-dependent hair growth; independent of HPG axis
- Urinary steroids can help differentiate from late-onset CAH / adrenal tumour [9]
- Increased risk of developing PCOS in later life [9]
GC Lecture Slide – High Yield Differential for Pubarche Only
From GC 149 lecture slide: [1]
Pubarche only (pubic hair, axillary hair/odour, and acne):
- Rapid growth and significantly advanced bone age →
- Investigations: ↑Testosterone, ↑17-(OH)P, ↑DHEAS, adrenal US, ovarian US
- Possible diagnosis/source: CAH, NCAH (non-classical CAH), or adrenal tumour; exogenous source of androgen
- Normal growth rate and mildly advanced bone age, 5–7 years of age →
- Investigations: prepubertal testosterone, normal 17-(OH)P, ± pubertal DHEAS
- Diagnosis: idiopathic precocious adrenarche
This slide is commonly examined. The key discriminator is growth rate and degree of bone age advancement — if markedly advanced, think CAH or tumour. If mild, think benign adrenarche.
- Isolated menstruation in girls < 9 years; aetiology unknown [2]
- Need to rule out: foreign body, local mass, McCune-Albright syndrome [2]
- Clinical features: functional ovarian cyst; ↑risk of accelerated bone maturation (∵↑oestrogen) [2]
- Other considerations: vulvovaginitis, sexual abuse, urethral prolapse (may be confused with vaginal bleeding)
- Development of gonadarche (breast or testicular enlargement) with pubarche (pubic or axillary hair) with either no progression or intermittent slow progression in clinical pubertal signs [7]
- This is a grey zone — may need longitudinal follow-up to determine if it truly remains non-progressive
Once a pathological cause is suspected (i.e., progressive, multiple pubertal features, advanced bone age), the next critical step is to determine the source of the sex steroids.
| Feature | Central PP (CPP) | Peripheral PP (PPP) |
|---|---|---|
| Mechanism | Premature activation of HPG axis → ↑gonadotropin [2] | Exogenous/autonomous oestrogen or androgen hyperproduction [2] |
| Hormone pattern | ↑LH, FSH → ↑oestrogen, testosterone [2] | ↑oestrogen/testosterone → ↓LH, FSH [2] |
| Development | Always isosexual (appropriate for sex) [2], consonant | Can be iso- or contrasexual [2], dissonant |
| Testes in boys | Bilateral enlargement (≥ 4 mL) | Prepubertal (adrenal/exogenous source) OR unilateral (gonadal tumour) |
| Proportion of cases | 10–20% [2] | ~10% [2] |
| Key imperative | Must exclude CNS tumours (especially in males) [2] | Identify source: adrenal, gonadal, exogenous, syndromic |
Tier 3: Specific Aetiological Differential Diagnoses
| Aetiology | Key Features / Clues | Notes |
|---|---|---|
| Idiopathic | Diagnosis of exclusion; 80% in females, ~10% in males [2] | In males, any underlying CNS pathology should ALWAYS be sought [2] |
| Hypothalamic hamartoma | Most common tumour cause [2]; pathognomonic gelastic (laughing) seizures [9]; non-progressive mass | Contains ectopic GnRH neurons firing autonomously |
| Optic glioma | Often in context of NF1 [8]; visual impairment, proptosis | Chiasmal/hypothalamic location disrupts inhibitory pathways |
| Other CNS tumours | Astrocytoma, ependymoma, pineal gland tumours [2] | May present with headache, vomiting, visual field defects, seizures |
| Hydrocephalus | Congenital CNS abnormality [2] | ↑ICP disrupts hypothalamic inhibitory circuits |
| Acquired CNS insults | Post-irradiation, infection, surgery, head injury [2] | Low-dose cranial irradiation (18–24 Gy) paradoxically causes CPP |
| Primary hypothyroidism | Listed under CPP in some classifications because TSH cross-reacts with FSH receptor [2][7]; however, mechanistically it is FSH-driven (i.e., gonadotropin-independent at the level of LH); some references classify under PPP | Delayed bone age with poor growth velocity — unique among all PP causes; excellent prognosis with treatment [2] |
| Genetic | MKRN3 loss-of-function (most common familial CPP gene), KISS1/KISS1R gain-of-function [9] | Paternally inherited in MKRN3 |
| Previous excess sex steroid exposure | Postulated priming effect of peripheral precocity-derived sex steroids on hypothalamus [9] | PPP can "trigger" secondary CPP |
Classification Caveat – Primary Hypothyroidism
Primary hypothyroidism is a favourite exam trap. Different sources classify it differently:
- Some place it under CPP because the mechanism involves FSH receptor stimulation (a gonadotropin receptor) [2][9]
- Others classify it under PPP because the drive comes from TSH, not from true GnRH pulsatility — the HPG axis is not truly activated [7]
For HKU exams: The GC 149 lecture and Felix Lai notes list it under both CPP and PPP differentials [7][9]. The critical teaching point is the mechanism (TSH cross-reactivity with FSH receptor due to shared α-subunit) and the unique finding (delayed bone age + poor growth). Know the mechanism and you'll be fine regardless of classification.
From Felix Lai senior notes — structured differential: [7]
| Type | Aetiology | Key Features / Pathophysiology |
|---|---|---|
| Isosexual | Leydig cell tumour | Testosterone-secreting; considered in any male with asymmetrical testicular enlargement [7] |
| hCG-secreting tumours | hCG is molecularly similar to LH. Germ cell tumours or hepatoblastoma produce hCG → activates LH receptors on Leydig cells → ↑testosterone [2][7][10]. Increase in testicular size is less than expected or no enlargement since most of the testes is made up of tubular elements (Sertoli cells) whose maturation depends upon FSH [7] | |
| Familial male-limited PP (testotoxicosis) | Caused by activating mutation of LH receptor gene → premature Leydig cell maturation and testosterone secretion [7]. Autosomal dominant; boys only | |
| CAH | Enzymatic defect in adrenal steroid biosynthesis; sex hormone levels vary depending on the adrenal enzyme block; e.g., 21-hydroxylase deficiency, 11β-hydroxylase deficiency [7] | |
| Adrenocortical tumours (androgen-secreting) | Autonomous androgen production | |
| Exogenous androgen | Topical testosterone creams, TCM | |
| Contrasexual | Adrenocortical tumours (oestrogen-secreting) | Feminisation in a boy (gynaecomastia) |
| Exogenous oestrogen | Accidental exposure |
Why hCG-Secreting Tumours Do NOT Cause PP in Girls
hCG-secreting tumours do NOT lead to precocious puberty in females since oestrogen biosynthesis requires both activation of LH and FSH receptors [7][10]. hCG mimics LH only — it does not activate FSH receptors. In males, LH receptor activation alone is sufficient to stimulate Leydig cells → testosterone. But in females, both LH (theca cells → androgens) AND FSH (granulosa cells → aromatase → oestradiol) are needed for oestrogen production. Without FSH, the pathway is incomplete. This is a commonly tested concept.
From Felix Lai senior notes: [7]
| Type | Aetiology | Key Features / Pathophysiology |
|---|---|---|
| Isosexual | Ovarian cysts | Functioning follicular ovarian cyst is the most common cause of peripheral precocity in girls [7]; autonomous oestrogen secretion → breast development ± vaginal bleeding |
| Ovarian tumours | Development of either isosexual or contrasexual precocity depending on tumour type [7]; granulosa cell tumours → oestrogen; Sertoli-Leydig → androgens | |
| McCune-Albright syndrome | Clinical triad = polyostotic fibrous dysplasia (bone) + café-au-lait spots (skin) + peripheral precocity [7]. Somatic mutation of the α-subunit of Gs protein that activates adenylyl cyclase → autonomous hyperfunction of many endocrine glands (LH/FSH/GH/ACTH/TSH) [7]. Occurs predominantly in girls presenting with vaginal bleeding that precedes breast development [7] | |
| Primary hypothyroidism | TSH is molecularly similar to FSH; cross-reactivity and stimulation of FSH receptor by high serum TSH concentration since they both share common α-subunit [7] | |
| Adrenocortical tumours (oestrogen-secreting) | Autonomous oestrogen | |
| Exogenous oestrogen | OCP, phytoestrogens in TCM | |
| Contrasexual | Ovarian tumours (androgen-secreting) | Virilisation in a girl |
| CAH | 21-hydroxylase deficiency, 11β-hydroxylase deficiency [7]; virilisation (clitoromegaly, pubic hair, acne) | |
| Adrenocortical tumours (androgen-secreting) | Virilisation | |
| Exogenous androgen |
| Condition | Why It Mimics PP | How to Distinguish |
|---|---|---|
| Lipomastia (adipomastia) | Fat deposition in breast area in obese prepubertal children mimics thelarche | No glandular tissue palpable; normal bone age; no other pubertal signs |
| Exogenous oestrogen/testosterone exposure | Lavender/tea tree oil products, TCM, parental topical hormone creams | Careful drug/exposure history; levels normalise after removal of source |
| Foreign body / vulvovaginitis | Vaginal bleeding/discharge may mimic premature menarche | Per rectal/per vaginal examination, vaginoscopy; no systemic pubertal signs |
| Sexual abuse | May present with genital trauma, bleeding, or behavioural changes | Non-accidental injury screen; safeguarding protocols |
| Peutz-Jeghers syndrome | Sertoli cell tumour of ovary → autonomous oestrogen → isosexual PP in girls | Mucocutaneous pigmentation, GI polyps; rare |
| Hepatoblastoma | hCG-secreting → PP in boys [10] | Abdominal mass, ↑AFP, ↑β-hCG |
| Gigantism (GH excess) | May present with rapid growth but no true pubertal signs | GH-producing pituitary adenoma [5]; ↑IGF-1; no sex steroid elevation |
| Adrenal Cushing syndrome | Adrenocortical tumour may co-secrete androgens → virilisation | Cushingoid features, ↑cortisol, ↑androgens; adrenal mass on imaging [11] |
Pathophysiology of PPP postulated to be related to xenoestrogen (e.g., environmental chemical pollutants in air/water/food chain) → share similar chemical structure and mimic natural oestrogen → stimulate target tissues [2]
In Hong Kong, relevant exposures include:
- Bisphenol A (BPA) — plastics, food containers, thermal paper
- Phthalates — plastic toys, personal care products
- Pesticides (organochlorines)
- Phytoestrogens — soy-based infant formulas, TCM
- Meat/poultry treated with growth-promoting hormones (less regulated in some imported products)
While the epidemiological evidence is not definitive, the secular trend towards earlier puberty worldwide is at least partly attributable to improved nutrition, rising obesity rates, and endocrine disruptor exposure.
| Category | Aetiology | Iso/Contra-sexual | LH/FSH | Bone Age | Unique Clue |
|---|---|---|---|---|---|
| Normal variant | Premature thelarche | Iso (F) | Prepubertal | Normal | Isolated, non-progressive, waxes/wanes |
| Normal variant | Premature adrenarche | — | Prepubertal | Normal/mild ↑ | Pubic hair only, ↑DHEAS, r/o CAH |
| Normal variant | Isolated menarche | Iso (F) | Inconsistent | Normal/mild ↑ | r/o foreign body, McCune-Albright |
| CPP | Idiopathic | Iso | ↑ | Advanced | Diagnosis of exclusion; 80% girls |
| CPP | Hypothalamic hamartoma | Iso | ↑ | Advanced | Gelastic seizures, non-progressive mass |
| CPP | Optic glioma | Iso | ↑ | Advanced | NF1, visual loss |
| CPP | Post-irradiation | Iso | ↑ | Advanced | History of cranial RT |
| PPP | CAH | Contra (F), Iso (M) | ↓ | Advanced | Ambiguous genitalia (neonatal), ↑17-OHP |
| PPP | McCune-Albright | Iso (F) | ↓ | Advanced | Café-au-lait + fibrous dysplasia + PP |
| PPP | Ovarian cyst | Iso (F) | ↓ | Advanced | Most common PPP cause in girls |
| PPP | Leydig cell tumour | Iso (M) | ↓ | Advanced | Unilateral testicular enlargement |
| PPP | hCG-secreting tumour | Iso (M) | ↓ | Advanced | ↑β-hCG; hepatoblastoma, germ cell tumour |
| PPP | Testotoxicosis | Iso (M) | ↓ | Advanced | FHx, boys only, bilateral mild testicular ↑ |
| PPP | 1° hypothyroidism | Iso | ↓ LH but ↑TSH→FSH-R | Delayed | Only PP cause with delayed BA and poor growth |
| PPP | Exogenous steroids | Variable | ↓ | Variable | Drug/TCM/exposure history |
Key exam-ready distinguishing points:
- Consonant + isosexual = CPP; dissonant or contrasexual = PPP [2]
- Isolated contrasexual development excludes CPP [7]
- In boys, always look for CNS pathology (CPP is rarely idiopathic in boys) [2]
- Functioning follicular ovarian cyst = most common cause of PPP in girls [7]
- hCG-secreting tumours cause PP in boys only (oestrogen biosynthesis needs both LH + FSH receptor activation) [7]
- McCune-Albright: vaginal bleeding precedes breast development [7]
- 1° hypothyroidism = ONLY cause with delayed bone age + poor growth [2]
- Pubarche only + rapid growth + significantly advanced BA → think CAH / adrenal tumour; normal growth + mildly advanced BA → idiopathic precocious adrenarche [1]
Active Recall - Differential Diagnosis of Precocious Puberty
References
[1] Lecture slides: GC 149. Premature puberty puberty and related disorders.pdf (Pubarche only differential slide, p59) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf (Pages 70–71, Precocious Puberty) [5] Senior notes: Maksim Medicine Notes.pdf (Page 108, Acromegaly and McCune-Albright) [7] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Pages 674–675, Peripheral precocity differentials and benign variants) [8] Senior notes: Ryan Ho Rheumatology.pdf (Page 172, NF1 diagnostic criteria and pubertal surveillance) [9] Senior notes: Maksim Paediatric Notes.pdf (Page 46–47, Premature sexual development) [10] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (Page 1078, Hepatoblastoma and hCG) [11] Senior notes: Block A - I have fluctuating BP_ cushing syndrome; adrenal diseases and tumours; other endocrine tumours.pdf (Cushing syndrome differentials)
Diagnostic Criteria, Algorithm, and Investigations for Precocious Puberty
1. Diagnostic Criteria
There is no single "diagnostic criteria checklist" for precocious puberty in the way that exists for, say, rheumatoid arthritis or SLE. Instead, diagnosis is a stepwise clinical-biochemical-radiological process built on answering a sequence of clinical questions. The framework comes directly from the lecture materials.
Key questions to answer: [2]
- Is onset of puberty before 8y (F) or 9y (M)? — ascertain precocious puberty
- Are there any progression of clinical symptoms? — normal variation vs pathological
- Are there any biological/radiological signs of exaggerated maturation?
- Is the PP gonadotropin-dependent or independent? — central vs peripheral PP → if central → idiopathic vs tumour
- Is the predicted adult height affected?
- Are there any psychological consequences?
| Criterion | Detail |
|---|---|
| Age threshold | Secondary sexual characteristics before 8 years (girls) or 9 years (boys) |
| What counts as pubertal onset? | Girls: breast bud (Tanner B2) — NOT pubic hair alone. Boys: testicular volume ≥ 4 mL (Tanner G2) |
| Progression | Must demonstrate progressive development over 4–6 months to distinguish from benign variants |
| Parameter | CPP (Central) | PPP (Peripheral) | Benign Variant |
|---|---|---|---|
| Basal LH | > 0.2 mIU/L (pubertal range) [2] | < 0.2 mIU/L (prepubertal range) [2] | Prepubertal |
| GnRH/GnRHa stimulation test | Peak stimulated LH elevated to pubertal range [7] | LH remains suppressed | LH remains prepubertal |
| Peak LH:FSH ratio | > 0.66 → CPP [7] | < 0.66 or suppressed | < 0.66 → benign/non-progressive variant [7] |
| Stimulated oestradiol/testosterone | Elevated after GnRHa administration [7] | — (already elevated basally from autonomous source) | Normal |
| Sex steroids | ↑ (concordant with ↑LH/FSH) | ↑ (discordant — high sex steroids with low/suppressed gonadotropins) | Normal or mildly ↑ |
| Bone age | Advanced > 2 yr | Advanced > 2 yr (except hypothyroidism → delayed) | Normal or mildly advanced |
GnRH Stimulation Test – The Confirmatory Test for CPP
GnRH or GnRHa (leuprolide) stimulation test: [7]
- Differentiates CPP from benign or non-progressive pubertal variant in patients in whom the clinical picture is discordant with initial baseline investigations
- Procedure: measurement of serum LH concentration before and after administration of GnRH/GnRHa at 0, 30, and 60 mins; measurement of oestradiol and testosterone 24 hours later
- Peak stimulated LH elevated to pubertal range → indicates CPP
- Peak LH:FSH ratio > 0.66 → CPP; < 0.66 → benign/non-progressive variant
- Elevated oestradiol or testosterone level after GnRH agonist administration → CPP
Why does this work? In CPP, the GnRH receptors on pituitary gonadotrophs have been "primed" by ongoing endogenous pulsatile GnRH secretion. When you give an exogenous bolus of GnRH/GnRHa, these primed gonadotrophs mount a robust, exaggerated LH response. In prepubertal children or benign variants, the gonadotrophs are quiescent and unprimed, so the LH response is flat.
2. Diagnostic Algorithm
The algorithm follows the principle of sequence of investigations: history and PE → baseline blood tests → screening biochemistry → confirmatory tests → imaging → invasive tests [12]. In endocrine workup, biochemistry must come before imaging because modern imaging resolution is so high that incidental benign lesions may be found that are unrelated to the clinical condition [12].
From GC 149 lecture slide (Nakamoto et al.): [1]
This is a high-yield in-house exam algorithm. It separates girls by their presenting feature:
High Yield — GC 149 Lecture Slide Algorithm
Pubarche only: [1]
- Rapid growth and significantly advanced BA → Ix: ↑Testosterone, ↑17-(OH)P, ↑DHEAS, adrenal US, ovarian US → Dx: CAH, NCAH, or adrenal tumour; exogenous source of androgen
- Normal growth rate and mildly advanced BA, 5–7 years of age → Ix: prepubertal testosterone, normal 17-(OH)P, ± pubertal DHEAS → Dx: idiopathic precocious adrenarche
Thelarche only: [1]
- Normal growth rate and non-advanced BA, birth–3 years of age → Ix: prepubertal LH and FSH, pubertal oestradiol → Dx: idiopathic precocious thelarche
- Rapid growth and significantly advanced BA → Ix: prepubertal LH and FSH, pubertal oestradiol → Dx: McCune-Albright syndrome; exogenous source of oestrogen
These are directly examinable lecture-slide points. Know them cold.
3. Investigation Modalities — Detailed Interpretation
The principle of endocrine investigation: less invasive before more invasive; biochemistry before imaging [12].
3.1 Hormonal Profile — First-Line Screening
LH: for initial screening [2]
| Value | Interpretation | Why? |
|---|---|---|
| < 0.2 mIU/L (prepubertal range) | Normal variant or peripheral PP [2] | The HPG axis has not been activated; any sex steroid elevation must be from a non-central source |
| > 0.2 mIU/L (pubertal range) | Central PP [2] | The pituitary is responding to pulsatile GnRH — the HPG axis is active |
Technical note: Use a 3rd-generation immunoassay (sensitivity < 0.1 mIU/L) — older assays may not reliably detect the prepubertal/pubertal threshold. Random daytime LH may be misleading because early pubertal GnRH pulsatility occurs nocturnally first. If clinical suspicion is high but basal LH is equivocal, proceed to GnRH stimulation test.
FSH: limited diagnostic value due to overlap between prepubertal and pubertal stages [2]
Why is FSH less useful than LH? Because FSH levels have a much wider normal range and there is substantial overlap between prepubertal and early pubertal values. FSH rises earlier and more gradually, making it a poor discriminator. However, FSH is still measured because it is needed to calculate the LH:FSH ratio after stimulation testing.
Oestrogen, testosterone: interpret together with LH/FSH [2]
| Pattern | Interpretation |
|---|---|
| ↑Sex steroids + ↑LH/FSH | CPP — HPG axis driving sex steroid production |
| ↑Sex steroids + ↓LH/FSH | PPP — autonomous/exogenous sex steroids with negative feedback suppressing gonadotropins |
| Normal sex steroids + prepubertal LH/FSH | Benign variant or very early PP — repeat in 3–6 months |
Oestradiol in girls: > 20 pg/mL suggests pubertal levels. However, oestradiol fluctuates widely (pulsatile secretion, follicular activity) and a single measurement can be misleading.
Testosterone in boys: interpret with Tanner stage. In early CPP, testosterone may still be in the low-pubertal range.
Measurement of DHEAS may help to distinguish testicular and adrenal source of androgens [7]
| Finding | Interpretation |
|---|---|
| Mildly elevated DHEAS (age-appropriate for early puberty) | Premature adrenarche — benign |
| Markedly elevated DHEAS | Adrenal tumour or CAH (zona reticularis overactivity) |
| Normal DHEAS with elevated testosterone | Gonadal source (testicular Leydig cell tumour, CPP) |
DHEAS is the most abundant adrenal steroid in blood and a single measurement is commonly used as a marker of adrenal androgen secretion. It has a long half-life (~8 hours) and minimal diurnal variation, making it more reliable than DHEA.
This is the gold-standard confirmatory test for CPP when basal LH is equivocal or when clinical findings are discordant with initial labs.
GnRH or GnRHa (leuprolide) stimulation test: [7]
| Step | Detail |
|---|---|
| Agent | Synthetic GnRH (gonadorelin) 100 µg IV bolus; OR GnRH agonist (leuprolide acetate) 20 µg/kg SC (max 500 µg). Leuprolide is more widely available and has largely replaced native GnRH in many centres including HK [7] |
| Sampling | Serum LH at 0, 30, and 60 minutes [7] |
| Additional | Oestradiol and testosterone measured 24 hours later [7] |
| CPP confirmed if | Peak stimulated LH elevated to pubertal range (typically > 5 mIU/L with GnRHa, or > 8 mIU/L with native GnRH, though thresholds vary by assay) [7] |
| LH:FSH ratio | > 0.66 → CPP; < 0.66 → benign/non-progressive variant [7] |
| Stimulated sex steroids | Elevated oestradiol or testosterone after GnRH agonist → CPP [7] |
Why LH:FSH ratio matters: In true central puberty, the pubertal rise in LH is proportionally greater than FSH (LH dominance). In prepubertal or early benign states, FSH tends to be higher relative to LH (FSH dominance). A ratio > 0.66 reflects the LH-dominant pattern of true pubertal activation.
Interpreting the GnRH Stimulation Test
A common mistake is to interpret a "normal" LH peak as excluding CPP. Remember:
- Very early CPP may have a borderline response — repeat in 3–6 months if clinical suspicion remains
- The test can also be falsely "positive" in some girls with premature thelarche (particularly the exaggerated/atypical form)
- Clinical context always trumps a single test result — use the stimulation test to support, not replace, clinical judgement
Other hormones: [2]
| Investigation | Purpose | Key Findings |
|---|---|---|
| TFT | Rule out primary hypothyroidism [2][7] | ↑TSH with ↓fT4 → primary hypothyroidism. This is the only cause of PP with delayed bone age and poor growth. TSH cross-reacts with FSH receptors (shared α-subunit) |
| Prolactin | Rule out prolactinoma [2] | ↑Prolactin > 200 ng/mL suggests prolactinoma. A pituitary macroadenoma could cause both hyperprolactinaemia (stalk compression) and CPP (pressure on hypothalamus) |
| β-hCG | Rule out hCG-secreting tumour [2][7] | Evaluate for possibility of hCG-secreting tumour in males [7]. Elevated in germ cell tumours, hepatoblastoma. hCG mimics LH → activates Leydig cells → ↑testosterone (boys only) |
| 17-OHP (17-hydroxyprogesterone) | Androgen workup for CAH [2] | > 200 ng/dL (> 6 nmol/L) baseline is suggestive; > 1000 ng/dL (> 30 nmol/L) on ACTH stimulation confirms classical 21-hydroxylase deficiency |
| DHEAS | Adrenal androgen marker | See above (section 3.1.4) |
| Testosterone | Gonadal vs adrenal source in boys | Interpret with testicular exam and DHEAS |
| 24-hour urine free cortisol | Rule out Cushing syndrome [2] | If virilisation with Cushingoid features → adrenocortical tumour may co-secrete androgens and cortisol |
| ± Synacthen (ACTH stimulation) test | Confirm CAH if 17-OHP borderline [2] | Exaggerated 17-OHP rise after 250 µg synacthen IV → confirms enzyme block in steroidogenesis |
3.4 Radiological Investigations
XR hand and wrist for bone age (advanced bone age suggests true PP) [2]
This is a critical first-line investigation in every child with suspected PP.
| Finding | Interpretation | Mechanism |
|---|---|---|
| Advanced bone age (> 2 SD or > 20% above chronological age) | True precocious puberty (CPP or PPP) | Sex steroids accelerate skeletal maturation → chondrocyte hypertrophy and ossification in growth plates |
| Normal bone age | Benign variant (premature thelarche, adrenarche) or very early PP | Insufficient sex steroid exposure to accelerate skeletal maturation |
| Delayed bone age | Primary hypothyroidism | Hypothyroidism retards skeletal maturation — this OVERRIDES the pro-maturational effect of the (modest) sex steroid exposure from TSH-FSH cross-reactivity |
Interpretation from Felix Lai notes: [15]
- Advanced bone age: Precocious puberty / Hyperthyroidism
- Delayed bone age: Constitutional delay of growth and puberty (CDGP) / Systemic disease / Hypothyroidism / GH deficiency / Cushing's syndrome
Method: The Greulich-Pyle atlas (comparing the radiograph against standard reference images) or the TW3 (Tanner-Whitehouse 3) method (scoring individual bone centres) are used. The GP method is quicker; TW3 is more precise but time-consuming.
Clinical utility beyond diagnosis: Bone age is used to calculate predicted adult height (e.g., Bayley-Pinneau tables). If predicted adult height is significantly compromised (< 150 cm or > 2 SD below mid-parental height), this may be an indication for treatment even in slowly progressive cases.
MRI brain/pituitary for CNS lesions [2]
| Indication | What to Look For |
|---|---|
| All boys with confirmed CPP | In males, CNS pathology should ALWAYS be sought [2] — idiopathic CPP is rare in boys (~10%) |
| Girls with CPP < 6 years | Higher likelihood of CNS pathology in very young girls |
| Girls with CPP 6–8 years | May be deferred if no neurological symptoms and idiopathic CPP is suspected clinically, but many centres still perform MRI routinely |
| Any child with neurological symptoms | Headache, visual field defects, seizures (especially gelastic seizures), papilloedema |
| Not needed for confirmed PPP or benign variants | Unless clinical features suggest a specific lesion (e.g., McCune-Albright with bony lesions) |
Key MRI findings in CPP:
| Lesion | MRI Appearance | Clinical Clue |
|---|---|---|
| Hypothalamic hamartoma | Small pedunculated mass attached to the tuber cinereum or the floor of the 3rd ventricle [14] | Gelastic seizures, very young onset CPP, non-progressive mass |
| Optic pathway glioma | Enhancing mass along optic nerve/chiasm/tract | NF1 context, visual impairment |
| Astrocytoma / ependymoma | Variable enhancing mass in hypothalamic/third ventricular region | Headache, vomiting, papilloedema |
| Pineal tumour | Mass in pineal region, possible hydrocephalus | Parinaud syndrome (upward gaze palsy), ↑β-hCG if germinoma |
| Post-irradiation changes | White matter signal changes, hypothalamic atrophy | History of cranial RT for leukaemia or brain tumour |
| Normal pituitary | May show physiological enlargement of pituitary in early puberty | Idiopathic CPP — diagnosis of exclusion |
US pelvis/adrenal for tumours [2]
| Finding | Interpretation |
|---|---|
| Uterine length > 3.4 cm, pear-shaped configuration | Pubertal uterus → significant oestrogen exposure (supports CPP or PPP with oestrogen source) |
| Prepubertal uterus (tubular, < 3.4 cm) | Benign variant, premature adrenarche (no significant oestrogen) |
| Endometrial echo present | Oestrogen-stimulated endometrium → supports pubertal status |
| Ovarian volume > 1–3 mL, multiple follicles > 4 mm | Pubertal ovaries; in CPP, bilateral symmetric stimulation |
| Unilateral ovarian cyst > 9 mm or mass | Functioning follicular ovarian cyst (most common PPP cause in girls) or ovarian tumour (granulosa cell) |
| Adrenal mass | Adrenocortical tumour (androgen or oestrogen secreting) or CAH with adrenal hyperplasia |
US testis: [2]
| Finding | Interpretation | Why? |
|---|---|---|
| Bilateral enlargement (≥ 4 mL) | CPP (∵↑gonadotropin) [2] | LH and FSH stimulate both testes symmetrically |
| Unilateral enlargement | Gonadal tumour [2] | Autonomous hormone production from one testis; considered in any male with asymmetrical testicular enlargement [7] |
| Prepubertal size (< 4 mL) | PPP (∵↓gonadotropin) [2] | Sex steroids from non-gonadal source (adrenal, exogenous); gonadotropins suppressed by negative feedback |
| Bilateral mild enlargement with PPP biochemistry | Consider testotoxicosis (familial male-limited PP) | Activating LH receptor mutation → Leydig cell activation without gonadotropin drive; testes enlarge but less than in CPP |
| Focal testicular lesion | Leydig cell tumour → testosterone-secreting [7]; also consider testicular adrenal rest tissue (TART) in CAH | USG-guided biopsy may be needed |
| Modality | Indication |
|---|---|
| Skeletal survey | McCune-Albright syndrome — polyostotic fibrous dysplasia (ground-glass lesions, typically unilateral) |
| CT/MRI adrenals | Adrenal mass suspected on USS or markedly elevated adrenal androgens |
| CT/MRI abdomen | Hepatoblastoma (hCG-secreting) if ↑β-hCG in a boy |
| Bone scintigraphy | McCune-Albright — to map extent of polyostotic fibrous dysplasia |
| Suspected Diagnosis | First-Line Investigations | Confirmatory / Second-Line |
|---|---|---|
| CPP | Basal LH (> 0.2), FSH, oestradiol/testosterone, bone age XR | GnRH stimulation test, MRI brain/pituitary |
| PPP — adrenal | 17-OHP, DHEAS, testosterone, adrenal US [1] | Synacthen test (CAH), 24h urine cortisol (Cushing), CT adrenals |
| PPP — gonadal (girls) | Oestradiol, pelvic US | Tumour markers if mass found |
| PPP — gonadal (boys) | Testosterone, testicular US, β-hCG | AFP (germ cell tumour), LH receptor mutation analysis (testotoxicosis) |
| PPP — hCG-secreting tumour | β-hCG, AFP, testicular US | CT/MRI abdomen (hepatoblastoma), CT chest (mediastinal GCT) |
| PPP — hypothyroidism | TFT (↑TSH, ↓fT4), bone age (delayed) | Thyroid antibodies, thyroid US |
| PPP — McCune-Albright | Oestradiol, pelvic US, bone age, skeletal survey | Genetic testing (GNAS1 — somatic, cannot always be detected in blood) |
| Benign variant — thelarche | Basal LH/FSH (prepubertal), oestradiol, bone age (normal), pelvic US (prepubertal uterus) | Observation ± GnRH stim if uncertain |
| Benign variant — adrenarche | Prepubertal testosterone, normal 17-(OH)P, ± pubertal DHEAS [1], bone age | Urinary steroids to differentiate from late-onset CAH |
5. Approach to History and Physical Examination — Structured
While covered in Part 1, the diagnostic approach is incomplete without reinforcing the systematic history and examination that guides investigation choice.
History: [2]
| Component | Specific Points | Rationale |
|---|---|---|
| Pubertal milestones | All 2° sexual characteristics — precise timing and sequence; isosexual or contrasexual (rule out CPP) [2] | Consonant progression → CPP; dissonant → PPP |
| Other S/S | Symptoms of CNS (headache, vomiting, VF defects, seizures) or hypothyroidism [2] | CNS lesion vs hypothyroidism as cause |
| PMH | Previous irradiation, head trauma, neonatal CNS infections [2] | Acquired CPP causes |
| Drug Hx | Exogenous steroids, TCM [2] | Exogenous PPP |
| Family Hx | Parental height [2] | Mid-parental height calculation for predicted height assessment; familial CPP (MKRN3) |
| Birth Hx | More common in children born SGA [2] | SGA → ↑risk of PP |
| Psychological impact | Impact on psychological health/wellbeing [2] | Guides need for psychosocial support and urgency of treatment |
Physical exam: [2]
| System | Key Findings | Significance |
|---|---|---|
| Height/weight with growth chart | Accelerated height velocity | True PP vs normal variant |
| Tanner staging | Quantify pubertal progress | Document stage and track over time |
| Neurocutaneous markers | Café-au-lait spots (McCune-Albright if irregular borders; NF1 if ≥ 6 with smooth borders) [2][8] | Guide towards specific aetiology |
| Neurological exam, optic fundi, VF | For CNS lesion [2] | Detect mass lesions causing CPP |
| Scoliosis / body asymmetry | [2] | NF1, spinal lesions |
| Thyroid exam | For hypothyroidism [2] | Goitre suggests primary hypothyroidism |
| Abdominal exam | Palpable mass | Ovarian tumour, adrenal tumour, hepatoblastoma |
| Testicular exam | Size (orchidometer), symmetry, masses | Bilateral ↑ (CPP), unilateral ↑ (tumour), prepubertal (PPP) |
High Yield Summary — Diagnostic Approach
- First-line screening: Basal LH (most useful single test), FSH, sex steroids, bone age XR
- Basal LH > 0.2 mIU/L → CPP; < 0.2 → PPP or benign variant [2]
- GnRH stimulation test confirms CPP: peak LH pubertal, LH:FSH > 0.66 [7]
- MRI brain is mandatory for all boys with CPP and girls < 6y with CPP
- Bone age advanced in all PP except primary hypothyroidism (delayed) [15]
- For pubarche only: discriminate by growth rate — rapid growth + advanced BA → CAH/tumour; normal growth + mild BA → benign adrenarche [1]
- For thelarche only: discriminate by age and growth — birth–3y + normal BA → premature thelarche; rapid growth + advanced BA → McCune-Albright or exogenous oestrogen [1]
- PPP workup by source: adrenal (17-OHP, DHEAS, adrenal US), gonadal (pelvic/testicular US), hCG (β-hCG), thyroid (TFT)
- Biochemistry before imaging in endocrine workup [12]
- Testicular US in boys: bilateral ↑ = CPP, unilateral ↑ = tumour, prepubertal = PPP
Active Recall - Diagnostic Criteria and Investigations for Precocious Puberty
References
[1] Lecture slides: GC 149. Premature puberty puberty and related disorders.pdf (Simplified diagnostic algorithm for girls, pp. 59–60; pubarche and thelarche only algorithms) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf (Page 73, Approach to Precocious Puberty — History, PE, Investigation) [7] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Pages 676–677, Diagnosis — GnRH stimulation test, history taking, physical examination) [8] Senior notes: Ryan Ho Rheumatology.pdf (Page 172, NF1 diagnostic criteria) [12] Senior notes: Block A - Introduction to Endocrine investigations.pdf (Principle 1: Sequence of investigations) [14] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Page 673, Aetiology of CPP — hypothalamic hamartoma MRI appearance) [15] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Page 666, Bone age determination and interpretation)
Management of Precocious Puberty
The management of precocious puberty is entirely driven by the type (central vs peripheral vs benign variant), the aetiology, and the clinical impact on the child. Think of it as a three-part framework:
- Is treatment needed at all? — benign variants require only observation
- What type of PP is it? — CPP and PPP require fundamentally different treatment strategies
- What are the goals of treatment? — preserve adult height, halt progression of sexual maturation, address psychological impact, and treat the underlying cause
Primary goal for CPP is to allow the child to grow to a normal adult height [7]
Decision for initiation of therapy depends on the age of onset, rate of sexual maturation, and estimated adult height as determined by rate of bone age advancement [7]
3. Management by Type
No intervention is required [7]
| Variant | Management | Rationale |
|---|---|---|
| Premature thelarche | Reassurance + observation every 6 months | Self-limiting; breast tissue may wax and wane; ~10–15% may progress to CPP → longitudinal follow-up essential |
| Premature adrenarche | Reassurance + observation; screen for CAH if clinical concern (rapidly progressive, clitoromegaly, significantly advanced bone age) | Early adrenal zona reticularis maturation is benign but must exclude non-classical CAH or adrenal tumour |
| Isolated premature menarche | Exclude foreign body, local mass, McCune-Albright → reassurance if workup negative | Unknown aetiology; rarely progresses |
| Non-progressive or intermittently progressive PP | Observation with serial Tanner staging, growth velocity, and bone age every 6–12 months | May never require treatment; intervene only if progression documented |
Why no treatment? Because these variants do not activate the full HPG axis, do not significantly advance bone age, and do not compromise final adult height. Treating them with GnRH agonists would be unnecessary and potentially harmful (suppressing what little normal pubertal activity may exist).
Communication with families: Parents often present in great anxiety. Careful explanation that this is a normal variant, not a disease, is the most important "treatment." Explain that follow-up is needed to confirm non-progression but that the vast majority resolve spontaneously.
3.2 Central Precocious Puberty (CPP)
Aim: preserve adult height potential, deal with psychological difficulty [2]
Specifically:
- Halt or slow the progression of secondary sexual characteristics
- Decelerate skeletal maturation to allow more time for linear growth → improve predicted adult height
- Prevent premature menarche and its psychosocial consequences in young girls
- Address psychological and social distress — body image, social isolation, risk of sexual exploitation
- Treat the underlying cause if identified (e.g., CNS tumour)
Not every child with CPP requires pharmacological treatment. Treatment is indicated when:
| Indication | Explanation |
|---|---|
| Age < 6–7 years at onset (girls) or < 9 years (boys) | Greater loss of growth potential; more time for bone age to advance |
| Rapidly progressive puberty | Fast Tanner stage advancement with accelerating growth velocity and bone age |
| Significantly compromised predicted adult height | Predicted height < 150 cm or > 2 SD below mid-parental target height |
| Bone age advanced > 2 years beyond chronological age | Indicates significant skeletal maturation with risk of premature epiphyseal fusion |
| Significant psychosocial distress | Child unable to cope emotionally with early physical maturation |
| Very early menarche | Girls at risk of menarche at age 7–8 — extremely distressing |
When treatment may NOT be needed in CPP:
- Girls aged 7–8 with slowly progressive CPP and acceptable predicted adult height — may be observed with serial bone ages
- If predicted height is within acceptable range and no psychological distress
3.2.3 GnRH Agonist (GnRHa) Therapy — First-Line Treatment for CPP
This is the cornerstone of CPP management and is a commonly examined topic.
GnRH agonists (GnRHa): [7]
Drug name breakdown: Leuprolide = "leu" (leucine) + "pro" (proline) — a synthetic peptide analogue of GnRH with amino acid substitutions that make it more potent and resistant to enzymatic degradation than native GnRH.
Underlying rationale = pituitary gonadotropic cells require pulsatile rather than continuous stimulation by GnRH to maintain ongoing release of gonadotropins [7]
GnRH agonist (GnRHa) is more potent and has longer duration of action than native GnRH, which will desensitise the gonadotropic cells of the pituitary to the stimulatory effects of endogenous GnRH after a brief period of stimulation [7]
Effectively decreases the ongoing release of gonadotropins and halts the progression of central precocious puberty (CPP) [7]
Let me explain this from first principles:
-
Normal physiology: GnRH is released from the hypothalamus in pulses (approximately every 60–90 minutes). This pulsatility is essential — the pituitary gonadotrophs have GnRH receptors that require intermittent stimulation-and-recovery cycles to maintain LH/FSH secretion.
-
What GnRH agonists do: When you give a GnRH agonist continuously (via depot injection), you overwhelm the pulsatile system:
- Days 1–7: Initial "flare" — transient increase in LH/FSH (because you're initially stimulating the receptors)
- Days 7–14: GnRH receptors on gonadotrophs become downregulated and desensitised (receptor internalisation, uncoupling from signalling cascades)
- After ~2 weeks: LH and FSH fall to prepubertal levels → sex steroid production ceases → pubertal progression halts
-
Why agonist, not antagonist? GnRH antagonists (e.g., degarelix) directly block GnRH receptors without the initial flare. While theoretically attractive, GnRH antagonists have not been investigated sufficiently and are not FDA approved [7] for paediatric CPP. GnRH agonists have decades of safety data in children and remain standard of care.
| Drug | Route | Frequency | Notes |
|---|---|---|---|
| Leuprolide acetate (Lupron) | IM | Every 4 weeks (Q4w) [2][7] | Most widely used; also available as 3-monthly (11.25 mg) or 6-monthly (45 mg) depot formulations |
| Triptorelin (Decapeptyl) | IM | Every 4 weeks or every 12 weeks (depot) | Used in some European and HK centres |
| Goserelin (Zoladex) | SC implant | Every 4 weeks or every 12 weeks | Less commonly used in paediatrics |
| Histrelin (Supprelin LA) | SC implant (arm) | Every 12 months | Subcutaneous rod implant providing continuous release; approved in the US; advantage of once-yearly dosing; requires minor surgical procedure for insertion/removal |
Paediatric dosing (leuprolide):
- 4-weekly depot: 7.5 mg IM (children < 25 kg), 11.25 mg IM (children 25–37.5 kg), 15 mg IM (children > 37.5 kg)
- 3-monthly depot: 11.25 mg or 30 mg IM
- Dose adjusted to achieve adequate suppression (monitored by stimulated LH)
Expected treatment results: [7]
- Decrease in growth rate generally to age-appropriate values
- Decrease in rate of osseous maturation leading to enhancement of predicted height
In practical terms:
- Breast tissue may regress or stabilise (regression more likely in younger girls)
- Pubic hair may persist (adrenal androgens are NOT suppressed by GnRH agonists — adrenarche is independent)
- Growth velocity slows to prepubertal rates (~5–6 cm/year)
- Bone age advancement slows, allowing predicted height to improve
- Menarche is prevented or ceases if already started
- Testicular size decreases in boys
| Parameter | Frequency | Target |
|---|---|---|
| Tanner staging | Every 3–6 months | No progression (or regression) of secondary sexual characteristics |
| Growth velocity | Every 3–6 months | Deceleration to age-appropriate prepubertal rate |
| Bone age XR | Every 6–12 months | Slowing of bone age advancement |
| Stimulated LH (GnRH or GnRHa stimulation) | 3–6 months after starting, then periodically | Suppressed LH confirms adequate gonadotroph desensitisation |
| Sex steroids | Periodically | Oestradiol < 20 pg/mL (girls); testosterone prepubertal (boys) |
| Predicted adult height | Serial calculation from bone age | Improving towards mid-parental target height |
How to Tell if GnRH Agonist is Working
After initiating treatment, perform a stimulated LH test (give a small dose of GnRHa and measure LH at 30–60 min). If peak LH remains suppressed (< 4 mIU/L), treatment is effective. If LH rises to pubertal levels despite therapy → consider dose increase, more frequent injections, or checking compliance.
In practice, basal LH alone is often used for monitoring (should be < 1 mIU/L on treatment).
Serum LH and sex hormone levels remain suppressed for as long as therapy is continued but puberty resumes promptly when therapy is stopped, typically at a "pubertal" chronological age [7]
- Treatment is continued until the child reaches an appropriate age for puberty (typically 11–12 years in girls, 12–13 years in boys) and an acceptable bone age/predicted height
- Upon discontinuation, puberty resumes within 3–12 months — gonadotropin secretion normalises rapidly
- Menarche typically occurs within 12–18 months of stopping treatment in girls
- Fertility is NOT affected — long-term follow-up studies show normal reproductive function
| Side Effect | Mechanism | Clinical Significance |
|---|---|---|
| Initial "flare" (first 1–2 weeks) | Transient GnRH receptor stimulation before desensitisation | May cause brief vaginal bleeding in girls (from oestrogen withdrawal after flare), breast tenderness; warn families in advance |
| Injection site reactions | Local inflammation from depot injection | Common; sterile abscess rare |
| Headache | Central effect of GnRH analogue | Usually mild and transient |
| Emotional lability / mood changes | Sex steroid fluctuations during initial flare; also psychological adjustment | Transient; provide family support |
| Weight gain | Multifactorial (reduced metabolic rate, altered body composition) | Monitor BMI; encourage healthy lifestyle |
| BMD concerns | Sex steroids are important for bone mineral accrual during puberty; suppression may reduce accrual | Studies show BMD recovers after treatment cessation and catches up by peak bone mass; no evidence of long-term osteoporosis risk |
| Allergic reaction | Hypersensitivity to depot formulation | Rare; switch to alternative preparation |
Reassurance About GnRH Agonist Safety
A common parental concern is about long-term effects on fertility and bone health. The evidence is reassuring:
- Fertility: Normal reproductive function and fertility after treatment discontinuation in long-term follow-up studies
- Bone density: Transient decrease during treatment but recovers after cessation; peak bone mass is ultimately normal
- Final height: Treatment improves predicted adult height by approximately 5–10 cm compared to untreated CPP (greatest benefit when treatment starts before age 6)
Addition of human GH to GnRHa can be considered in patients with markedly advanced bone age and prediction of short stature [7]
Rationale: GnRH agonist therapy slows growth velocity (which is the intended effect to slow bone maturation), but in some children with very advanced bone age, the remaining growth window is so narrow that height prognosis is still poor even with GnRH agonist. Adding recombinant GH can:
- Increase growth velocity while GnRHa continues to suppress bone maturation
- Improve predicted adult height beyond what GnRHa alone achieves
Indication: Typically considered when predicted adult height remains significantly below target despite adequate GnRH agonist therapy, particularly in children with:
- Bone age > 2–3 years advanced at start of treatment
- Poor growth velocity on GnRHa alone
- Co-existing GH deficiency (e.g., post-cranial irradiation — commonly associated with GH deficiency and patients should be treated with both GH and GnRH agonists [14])
3.3 Peripheral Precocious Puberty (PPP)
The fundamental principle is different from CPP:
PPP does NOT respond to GnRH agonist (GnRHa) therapy [7]
Why not? Because in PPP, the source of sex steroids is independent of the HPG axis. The pituitary gonadotrophs are already suppressed by negative feedback from the high sex steroids. Giving a GnRH agonist to suppress already-suppressed gonadotrophs achieves nothing.
Instead, management focuses on:
- Removal or blocking the production or response to excess sex steroids [7]
- Treating the underlying cause
Peripheral precocious puberty: depends on underlying causes [2]
| Cause | Management | Rationale |
|---|---|---|
| Tumour (adrenal, gonadal, hCG-secreting) | Surgical removal ± chemoRT [2] | Remove the autonomous source of sex steroids or hCG; chemotherapy for malignant tumours (hepatoblastoma, malignant germ cell tumours) |
| Large ovarian cyst | Drainage for large ovarian cyst [2] | Simple functional cysts may resolve spontaneously; large or symptomatic cysts require aspiration or cystectomy; aim to preserve ovarian tissue in children |
| Congenital adrenal hyperplasia (CAH) | Exogenous glucocorticoid for non-classical CAH [2]; classical CAH also requires glucocorticoid + mineralocorticoid replacement | Glucocorticoid (hydrocortisone) suppresses ACTH → reduces adrenal androgen overproduction. Paediatric dose: 10–15 mg/m²/day hydrocortisone divided in 2–3 doses. Stress dosing: double/triple during illness |
| Primary hypothyroidism | Levothyroxine replacement | Corrects the elevated TSH → removes the cross-stimulation of FSH receptors → PP resolves. This is one of the most gratifying treatments — PP reverses completely with thyroid replacement |
| Exogenous sex steroids / TCM | Remove the exogenous source | Identify and eliminate exposure (topical creams, dietary sources, TCM); PP regresses after removal |
| McCune-Albright syndrome | Anti-oestrogen agents (see below); aromatase inhibitors; manage bone lesions orthopaedically | No curative treatment for the underlying GNAS1 mutation; manage each endocrine manifestation individually |
| Familial testotoxicosis | Combination therapy: ketoconazole (inhibits steroidogenesis) + anti-androgen (e.g., spironolactone or bicalutamide) ± aromatase inhibitor | Need to block both testosterone synthesis AND action; once bone age approaches pubertal range, secondary CPP may develop → add GnRH agonist |
These agents are used when the source of sex steroids cannot be surgically removed (e.g., McCune-Albright, testotoxicosis):
| Drug | Class | Mechanism | Indication | Paediatric Considerations |
|---|---|---|---|---|
| Ketoconazole | Imidazole antifungal | Inhibits adrenal and gonadal steroidogenesis (blocks CYP17A1 and other cytochrome P450 enzymes) | Testotoxicosis, McCune-Albright (boys) | Monitor LFTs (hepatotoxicity risk); not first-line antifungal in this context but used specifically for anti-steroidogenic effect |
| Spironolactone | Aldosterone antagonist / anti-androgen | Blocks androgen receptor + mild inhibition of testosterone synthesis | Testotoxicosis (as adjunct) | Also causes anti-mineralocorticoid effects → monitor K⁺ |
| Bicalutamide | Non-steroidal anti-androgen | Pure androgen receptor antagonist | Testotoxicosis (alternative to spironolactone) | Fewer mineralocorticoid side effects |
| Letrozole / Anastrozole | Aromatase inhibitors | Block conversion of androgens → oestrogens | McCune-Albright (girls), testotoxicosis (to prevent oestrogen-mediated bone age advancement) | Used to reduce oestrogen exposure and slow skeletal maturation |
| Tamoxifen | Selective oestrogen receptor modulator (SERM) | Blocks oestrogen receptors in bone and breast | McCune-Albright (girls) — to slow bone age advancement and breast development | Limited paediatric data; used when aromatase inhibitors insufficient |
| Medroxyprogesterone acetate | Progestogen | Suppresses gonadotropin secretion + direct anti-oestrogenic effect on endometrium | Occasionally used for menstrual suppression in McCune-Albright | Not first-line; does not address underlying pathology |
| Hydrocortisone | Glucocorticoid | Suppresses ACTH → reduces adrenal androgen production | CAH | Paediatric dose: 10–15 mg/m²/day in 2–3 divided doses; use lowest effective dose to avoid Cushingoid effects |
| Fludrocortisone | Mineralocorticoid | Replaces aldosterone in salt-wasting CAH | Classical CAH (salt-wasting) | 100 µg/day; NaCl supplementation 1–2 g/day in infants |
An important concept: prolonged sex steroid exposure from PPP can "prime" the hypothalamus and trigger secondary activation of the HPG axis → the child develops secondary CPP on top of PPP.
Clue: The child with PPP (e.g., on treatment for CAH or testotoxicosis) begins to show:
- Rising LH despite ongoing anti-androgen/anti-oestrogen therapy
- Resumption of pubertal progression despite adequate control of peripheral sex steroids
Management: Add a GnRH agonist to the existing PPP-specific therapy to suppress the newly activated HPG axis.
| Aetiology | Specific Management Points |
|---|---|
| Hypothalamic hamartoma | Typically managed with GnRH agonist alone (for PP) ± anti-epileptics (for gelastic seizures). Surgery is not routinely indicated because hamartomas are benign and non-progressive; surgical resection carries risk of hypothalamic damage. Surgery is reserved for refractory seizures. |
| Optic glioma (NF1) | Chemotherapy (vincristine + carboplatin) is first-line if progressive; GnRH agonist for CPP. Avoid radiation in NF1 (↑risk of secondary malignancy) |
| Post-cranial irradiation CPP | GnRH agonist for CPP + GH therapy for concurrent GH deficiency [14] |
| Hepatoblastoma (hCG-secreting) | Surgical resection ± chemotherapy (cisplatin-based regimen); PP resolves once hCG-secreting tumour is removed |
| Leydig cell tumour | Testis-sparing surgery (enucleation) if feasible; radical orchiectomy if not. PP resolves after tumour removal |
| Granulosa cell tumour | Surgical resection (oophorectomy or ovarian-sparing if possible); chemotherapy if malignant. PP resolves after tumour removal |
This aspect is often overlooked but is explicitly part of the treatment goals.
| Aspect | Approach |
|---|---|
| Explaining the diagnosis | Age-appropriate explanation to the child; detailed explanation to parents/caregivers. Reassure that treatment is effective and reversible |
| Addressing parental anxiety | Many parents fear their child has cancer or will have permanent damage. Explain that most CPP is idiopathic and treatable |
| School and peer issues | Liaise with school if needed; child may need support for teasing or bullying |
| Body image | Normalise the child's experience; acknowledge that looking different from peers is distressing |
| Risk of sexual exploitation | A physically mature child is still cognitively and emotionally a child. Caregivers need to be aware of safeguarding risks |
| Psychological referral | Low threshold for clinical psychology or child psychiatry referral if emotional distress is significant |
| Consent and assent | Treatment decisions involve parents (consent) and the child's input (assent) as age-appropriate. Explain injections to the child, involve them in understanding their treatment |
5. Follow-Up and Long-Term Outcomes
| Visit | Assessments |
|---|---|
| Every 3–6 months | Height, weight, BMI, growth velocity, Tanner staging, psychological wellbeing |
| Every 6–12 months | Bone age XR, predicted adult height calculation |
| Periodically | Stimulated or basal LH to confirm suppression; sex steroid levels |
| As needed | MRI brain if initial imaging showed a lesion (monitor for progression) |
- Puberty resumes within 3–12 months of stopping GnRH agonist
- Menarche occurs ~12–18 months after discontinuation in girls
- Final adult height: Improved compared to untreated; median gain ~5–10 cm (greatest benefit with early treatment onset, < 6 years)
- Fertility: Normal — long-term follow-up studies show normal menstrual cycles, normal pregnancies
- BMD: Recovers after treatment cessation; peak bone mass is normal
- Psychological: Most children adjust well; continued support as needed during resumption of puberty
Exam Favourite — When to Stop GnRH Agonist
Stop when:
- Chronological age reaches an appropriate pubertal age (~11 years for girls, ~12 years for boys)
- Bone age is approximately 12–12.5 years in girls (just before the age at which most growth plate fusion occurs)
- Predicted adult height is acceptable (within target range)
- The child and family are psychologically ready for puberty to proceed
There is no rigid rule — this is an individualised decision made collaboratively with the family and child.
| Category | First-Line Treatment | Second-Line / Adjuncts | Key Points |
|---|---|---|---|
| Benign variant | No intervention required [7]; observation | — | Follow up every 6 months to confirm non-progression |
| CPP — idiopathic | GnRH agonist (IM leuprolide Q4w) [2][7] | ± GH if markedly advanced BA and short predicted height [7] | Monitor growth, bone age, suppression; stop at appropriate pubertal age |
| CPP — CNS lesion | Treat underlying lesion + GnRH agonist | Neurosurgery, chemo, RT as indicated | Hamartoma: usually GnRHa only (no surgery unless refractory seizures) |
| PPP — tumour | Surgical removal ± chemoRT [2] | — | PP resolves after source removed |
| PPP — ovarian cyst | Drainage [2] or observation (small cysts) | — | Preserve ovarian tissue |
| PPP — CAH | Exogenous glucocorticoid [2] + mineralocorticoid | ± GnRH agonist if secondary CPP develops | Hydrocortisone 10–15 mg/m²/day; stress dosing; monitor 17-OHP |
| PPP — hypothyroidism | Levothyroxine | — | PP reverses completely; excellent prognosis |
| PPP — McCune-Albright | Aromatase inhibitor ± tamoxifen | Letrozole or anastrozole | No cure for underlying mutation; manage endocrine manifestations |
| PPP — testotoxicosis | Ketoconazole + anti-androgen ± aromatase inhibitor | ± GnRH agonist if secondary CPP develops | Combination needed because blocking one pathway alone is insufficient |
| PPP — exogenous | Remove source | — | Identify TCM, creams, environmental exposure |
High Yield Summary — Management
- CPP first-line: GnRH agonist (leuprolide IM Q4w) — works by overriding pulsatile GnRH → desensitisation of pituitary gonadotrophs → ↓LH/FSH → ↓sex steroids [2][7]
- PPP does NOT respond to GnRH agonist — must treat the underlying cause [7]
- PPP management: surgical removal ± chemoRT for tumour; drainage for ovarian cyst; glucocorticoid for CAH [2]
- GnRH antagonists are NOT FDA approved for paediatric CPP [7]
- GH may be added to GnRHa in patients with markedly advanced bone age and prediction of short stature [7]
- Benign variants: no intervention required [7]
- Secondary CPP can develop from prolonged PPP → add GnRH agonist
- Primary hypothyroidism-related PP reverses completely with levothyroxine
- Puberty resumes promptly when GnRHa is stopped at appropriate chronological age [7]
- Family-centred care: Psychosocial support, age-appropriate communication, safeguarding awareness
Active Recall - Management of Precocious Puberty
References
[1] Lecture slides: GC 149. Premature puberty puberty and related disorders.pdf (Management of precocious puberty slide, p50) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf (Page 75, Treatment of PP) [7] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Page 679, Treatment — GnRHa mechanism, expected results, PPP management) [14] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (Page 673, CNS irradiation and GH deficiency) [16] Lecture slides: Block C - Premature puberty_ puberty and related disorders.pdf (Management of precocious puberty slide, p43)
Complications of Precocious Puberty
Complications of precocious puberty arise from three sources: (1) the disease itself — the biological consequences of premature sex steroid exposure; (2) the underlying aetiology — particularly CNS tumours or endocrine syndromes; and (3) treatment-related side effects. Each must be understood from the pathophysiology upwards.
1. Complications of the Disease Itself
This is the most important and most commonly examined complication.
Precocious puberty: ↑sex steroid → tall at diagnosis but ↓final height due to premature fusion [2]
Progresses rapidly and the accelerated bone maturation causes early fusion of bone plates and compromising final adult height [1]
Pathophysiology from first principles:
- Sex steroids (oestrogen is the final common mediator in both sexes — testosterone is aromatised to oestradiol at the growth plate) act on the epiphyseal growth plate chondrocytes
- Initially, oestrogen stimulates chondrocyte proliferation → growth acceleration → the child is tall for age early on
- With ongoing exposure, oestrogen promotes chondrocyte senescence and hypertrophy → accelerates the transition from proliferative to hypertrophic zone → eventual epiphyseal fusion
- The growth plates close years earlier than they would in normal puberty
- The total duration of linear growth is therefore curtailed → final adult height is shorter than genetic potential
Without treatment, children with untreated CPP may lose 10–20 cm of predicted adult height. The younger the onset, the greater the height loss.
Adult height preservation is particularly effective in girls < 6 years, with the greatest gain in adult height after treatment [1]
Those between 6 and 8 years form a more heterogeneous group — some with very rapid or advanced puberty may benefit; many with slowly progressive puberty yield a normal height outcome without treatment [1]
Little utility to treat girls over age 8 years for the purpose of increasing adult height [1]
High Yield – Height Compromise by Age of Onset
The degree of height compromise is inversely proportional to the age of onset:
- Onset < 6 years: Greatest height loss if untreated; greatest benefit from GnRH agonist treatment
- Onset 6–8 years: Heterogeneous — rapidly progressive cases benefit from treatment; slowly progressive cases may achieve near-normal height without intervention
- Onset > 8 years (girls): Little additional height gained from treatment — limited remaining growth to preserve
This concept is directly from the GC 149 lecture slide [1] and the European Society for Paediatric Endocrinology / Paediatric Endocrine Society consensus [1].
| Age of CPP onset | Estimated untreated final height loss | Treatment benefit |
|---|---|---|
| < 6 years | 10–20 cm below mid-parental target | Greatest (median gain ~5–10 cm) |
| 6–8 years | Variable (5–15 cm) | Moderate (depends on rate of progression) |
| > 8 years (girls) | Minimal (2–5 cm) | Minimal — observation often sufficient |
These are the second major indication for treatment and are explicitly stated in the lecture slides and consensus guidelines.
Reasons for treatment include: preservation of adult height potential; psychological difficulties with early puberty and menarche [1]
Pubertal onset occurring between 7–8 years should be evaluated if behaviour-based factors suggest a child's emotional state is adversely affected by early puberty and potential early menses [1]
| Complication | Mechanism / Explanation |
|---|---|
| Social isolation and peer difficulties | A child with adult-like body habitus is visually different from same-age peers → teasing, bullying, social exclusion. Cognitive and emotional maturity does NOT match physical appearance |
| Body image disturbance | The child may feel embarrassment or shame about breast development, body hair, or body odour at an age when these are not understood or expected |
| Behavioural problems | Sex steroids affect the limbic system → increased irritability, mood swings, aggression. The child lacks the emotional maturity to process these hormonal changes |
| Anxiety and depression | Documented higher rates of internalising disorders in children with PP compared to normally developing peers |
| Early menarche — psychosocial impact | A 6–7-year-old girl experiencing menstruation faces practical difficulties (managing pads at school, hygiene) and emotional distress. This is often the most distressing feature for families |
| Risk of sexual abuse and exploitation | A physically mature child is cognitively and emotionally still a child. The physical appearance of maturity may attract predatory behaviour. This is a safeguarding concern that must be explicitly addressed with caregivers |
| Early sexual behaviour | Some studies suggest (though controversially) that early physical maturity may be associated with earlier initiation of sexual activity in adolescence, though this is confounded by many psychosocial variables |
| Academic performance | Distraction, social difficulties, and emotional disturbance may impact school performance |
Family-Centred Care Reminder
Always assess psychological wellbeing at every clinic visit. Ask both the child (using age-appropriate language) and the caregiver separately. Low threshold for referral to clinical psychology or child psychiatry. The psychosocial burden may be as significant as the physical consequences, and it is often the primary driver for treatment even when height prognosis is acceptable.
Emerging evidence links early puberty (whether treated or untreated) with long-term metabolic risk:
| Complication | Mechanism |
|---|---|
| Obesity / increased BMI | Early sex steroid exposure alters fat distribution and appetite regulation; children with early puberty have higher rates of overweight and obesity in adolescence and adulthood |
| Insulin resistance and type 2 diabetes risk | Early oestrogen/androgen exposure → ↑insulin resistance; compounded if child is already obese or born SGA. ↑sex hormones and growth hormones in puberty may accelerate complications and worsen glycaemic control [17] |
| Polycystic ovary syndrome (PCOS) | Girls with premature adrenarche have ↑risk of developing PCOS in later life (hyperandrogenism, oligomenorrhoea, insulin resistance) — particularly those born SGA with rapid postnatal catch-up growth |
| Cardiovascular risk | Early menarche (< 12 years) is an independent risk factor for cardiovascular disease in adult women — postulated via prolonged lifetime oestrogen exposure, metabolic syndrome association, and psychosocial factors |
In untreated PP, the full pubertal cascade can result in:
- Ovulation and menstruation in young girls → theoretical risk of pregnancy in a child
- Spermatogenesis in young boys → theoretical fertility
While actual pregnancy is extremely rare in children with PP, this highlights the importance of safeguarding and early treatment.
2. Complications of the Underlying Aetiology
The complications here depend entirely on the specific cause of PP. These are not complications of PP per se but complications of the disease process causing it.
| Tumour | Specific Complications |
|---|---|
| Hypothalamic hamartoma | Gelastic (laughing) seizures — may be refractory to anti-epileptic medications; behavioural and cognitive difficulties; rarely, other seizure types (generalised, complex partial) may develop. The hamartoma itself is benign and non-progressive but seizures can significantly impact quality of life |
| Optic pathway glioma (NF1) | Progressive visual loss (visual acuity, visual fields); proptosis; hypothalamic dysfunction including obesity; NF1 surveillance required: BP, growth parameters, skin, skeletal, pubertal assessment, developmental assessment, eye and neuro follow-up [8] |
| Other CNS tumours (astrocytoma, ependymoma, pineal tumours) | Raised intracranial pressure (headache, vomiting, papilloedema, CN VI palsy), focal neurological deficits, hydrocephalus, endocrine deficiencies (panhypopituitarism if hypothalamic-pituitary region involved) |
| Post-cranial irradiation | Multiple anterior pituitary hormone deficiencies — most commonly GH deficiency (earliest to be lost), followed by gonadotropin deficiency, ACTH deficiency, TSH deficiency. Paradoxically, low-dose irradiation (18–24 Gy) causes CPP while higher doses (> 40 Gy) cause hypogonadism. Also risk of secondary CNS neoplasms |
| Syndrome | Specific Complications Beyond PP |
|---|---|
| McCune-Albright syndrome | Polyostotic fibrous dysplasia → pathological fractures, limb deformity, pain, facial asymmetry, optic nerve compression. Endocrine hyperfunction → GH excess (acromegaly/gigantism), hyperthyroidism, Cushing syndrome, renal phosphate wasting (rickets/osteomalacia). Café-au-lait spots — cosmetic. Risk of malignant transformation of fibrous dysplasia (rare, < 1%) |
| NF1 | Neurofibromas, optic tumours, skeletal lesions (scoliosis, tibial dysplasia), café-au-lait macules, Lisch nodules, learning difficulties (ADHD, ASD), cerebrovascular dysplasia (Moyamoya) [8]. Lifelong surveillance required |
| Congenital adrenal hyperplasia (CAH) | Adrenal crisis (salt-wasting form) — life-threatening hyponatraemia, hyperkalaemia, shock in neonatal period. Ambiguous genitalia in 46,XX females (virilisation). Short stature from androgen-driven premature epiphyseal fusion. Testicular adrenal rest tumours (TARTs) — ectopic adrenal tissue in testes, may impair fertility. Fertility issues — oligospermia in males, anovulation in females (improved with treatment). Increased cardiovascular risk and decreased BMD with long-term glucocorticoid therapy |
| Tumour | Complications |
|---|---|
| Hepatoblastoma (hCG-secreting) | Liver failure, intra-abdominal haemorrhage (tumour rupture), metastasis (lungs most common). AFP is elevated in ~90% |
| Germ cell tumours (hCG-secreting) | Site-dependent (mediastinal, intracranial, gonadal). Risk of metastasis. Elevated β-hCG and/or AFP as tumour markers |
| Adrenocortical carcinoma | Aggressive, often diagnosed late in children. Virilisation ± Cushing features. Liver and lung metastases. Poor prognosis if metastatic |
| Granulosa cell tumour (ovarian) | Oestrogen excess → endometrial stimulation → abnormal uterine bleeding. Risk of ovarian torsion. Juvenile type is more common in children; generally has a favourable prognosis if completely resected |
3. Treatment-Related Complications
| Complication | Mechanism | Clinical Significance |
|---|---|---|
| Initial flare reaction | First 1–2 weeks: transient ↑LH/FSH before receptor desensitisation | Brief vaginal bleeding (oestrogen withdrawal after flare), breast tenderness, mood changes. Warn families in advance — this does NOT mean treatment failure |
| Injection site reactions | Local inflammatory response to depot formulation | Pain, erythema, induration; rarely sterile abscess. Rotate injection sites |
| Transient decrease in bone mineral density | Suppression of sex steroids reduces bone mineral accrual during the normally rapid accrual phase of puberty | BMD recovers after treatment cessation and peak bone mass is ultimately normal in long-term studies. No evidence of increased adult osteoporosis risk |
| Weight gain | Multifactorial: altered body composition with reduced lean mass and increased fat mass; reduced metabolic rate with sex steroid suppression | Monitor BMI; encourage healthy diet and physical activity throughout treatment |
| Psychological impact of treatment | Repeated injections in a young child; awareness of being "different"; hormonal fluctuations | Age-appropriate explanation; involve child in treatment decisions; consider histrelin implant (annual) to reduce injection burden |
| Persistence of pubic hair | GnRH agonists suppress gonadotropins (LH/FSH) but do NOT suppress adrenal androgens (DHEAS) | Pubic hair (driven by adrenarche) may persist or progress despite effective gonadotropin suppression. This does NOT indicate treatment failure — explain to parents |
| Rare: anaphylaxis | Hypersensitivity to depot formulation | Extremely rare; switch to alternative preparation |
Common Parental Concern — Does Treatment Cause Infertility?
No. This is a very frequent question from parents. Long-term follow-up data spanning > 30 years confirms:
- Fertility is normal after GnRH agonist discontinuation
- Menstrual cycles resume within 12–18 months
- Pregnancies have been reported with normal outcomes
- No increased risk of reproductive malignancies
GnRH agonists produce a reversible pharmacological prepubertal state. Once stopped, the HPG axis reactivates fully.
| Drug | Complications | Monitoring |
|---|---|---|
| Ketoconazole | Hepatotoxicity (most important — can be severe); GI upset; adrenal insufficiency (inhibits cortisol synthesis at high doses) | LFTs every 4–6 weeks; cortisol levels; liver function baseline before starting |
| Spironolactone | Hyperkalaemia (aldosterone antagonism); GI upset; gynaecomastia (in boys — anti-androgen effect) | Serum K⁺ monitoring; renal function |
| Aromatase inhibitors (letrozole, anastrozole) | Potential impact on bone health (oestrogen is essential for bone mineral accrual); vertebral deformities reported in some paediatric studies; raised liver enzymes | BMD monitoring; LFTs; limited long-term paediatric safety data |
| Long-term glucocorticoid (for CAH) | Iatrogenic Cushing syndrome if overreplaced (growth suppression, obesity, striae, osteoporosis); adrenal crisis if underreplaced or not stress-dosed; poor growth if supraphysiological doses used | Growth velocity (most sensitive marker of over-replacement in children); bone age; morning 17-OHP and androstenedione to titrate dose |
| Surgical complications (tumour resection) | Hypothalamic damage (obesity, diabetes insipidus, temperature dysregulation); pituitary hormone deficiencies; surgical infection; haemorrhage | Post-operative endocrine screening; long-term anterior and posterior pituitary function monitoring |
| Outcome Domain | What to Monitor | Frequency |
|---|---|---|
| Final adult height | Height measurement after growth cessation; compare to mid-parental target | At completion of growth |
| Pubertal resumption | Tanner staging, growth velocity after treatment cessation | Every 6 months for 1–2 years after stopping GnRHa |
| Fertility | Menstrual history (girls); no routine fertility testing needed unless concerns | Adolescence / adulthood |
| Bone mineral density | DXA scan if prolonged treatment or risk factors | Case-by-case; typically recovers without intervention |
| Metabolic health | BMI, fasting glucose/insulin, lipid profile | Adolescence; especially if history of SGA, obesity, or premature adrenarche |
| Psychosocial wellbeing | Screening for anxiety, depression, body image issues, peer relationships | Every visit during and after treatment |
| Underlying aetiology | MRI brain (CNS lesion), endocrine axes (post-irradiation), tumour markers (malignancy) | Aetiology-specific; lifelong for syndromic causes |
High Yield Summary — Complications
- Compromised final adult height is the cardinal complication — premature epiphyseal fusion from sex steroid exposure. Height benefit of treatment is greatest when onset < 6 years [1]
- Psychological complications — body image, social isolation, bullying, early menarche distress, risk of sexual exploitation — are the second major indication for treatment [1]
- GnRH agonist side effects are generally mild and reversible: initial flare (warn families), injection site reactions, transient ↓BMD (recovers), weight gain, persistence of pubic hair (adrenal androgens not suppressed — NOT a treatment failure)
- Fertility is NOT impaired by GnRH agonist treatment — this is a key parental reassurance point
- Metabolic complications: ↑risk of obesity, insulin resistance, PCOS (especially premature adrenarche + SGA + obesity)
- Complications of the underlying cause (CNS tumour, CAH, McCune-Albright, NF1, hepatoblastoma) may be more clinically significant than PP itself and require cause-specific surveillance
- Ketoconazole hepatotoxicity is the most important drug-specific complication to monitor in PPP treatment
- Secondary CPP can develop from prolonged PPP — a complication of the disease that changes the treatment strategy
Active Recall - Complications of Precocious Puberty
References
[1] Lecture slides: GC 149. Premature puberty puberty and related disorders.pdf (pp. 17–19, 23–24, 36, 62, 64 — defining PP, pathological causes, treatment indications and height outcomes) [2] Senior notes: Adrian Lui Pediatrics Notes.pdf (Pages 66, 71 — tall stature from PP, pathological causes) [8] Senior notes: Ryan Ho Rheumatology.pdf (Page 172 — NF1 diagnostic criteria and surveillance) [16] Lecture slides: Block C - Premature puberty_ puberty and related disorders.pdf (Management of precocious puberty, p43) [17] Senior notes: Ryan Ho Endocrine.pdf (Page 94 — puberty accelerating diabetic complications)
High Yield Summary
- Definition: PP = secondary sexual characteristics before 8y (girls) or 9y (boys)
- CPP (gonadotropin-dependent): Premature activation of HPG axis → consonant, isosexual development. Idiopathic in 80% girls; always look for CNS pathology in boys.
- PPP (gonadotropin-independent): Autonomous sex steroid production → dissonant development, may be contrasexual. Causes: adrenal (CAH, tumour), gonadal (granulosa/Leydig cell tumour), hCG-secreting tumour, McCune-Albright, testotoxicosis, exogenous steroids, primary hypothyroidism.
- Normal variants: Premature thelarche, adrenarche, menarche — isolated, non-progressive, benign.
- Primary hypothyroidism is the ONLY cause with delayed bone age and poor growth — TSH cross-reacts with FSH receptors.
- Testicular size in boys is the most important clinical sign: bilateral ↑ = CPP; unilateral ↑ = tumour; prepubertal = PPP.
- Key concern: Premature epiphyseal fusion → compromised final adult height; psychological impact.
- Basal LH > 0.2 mIU/L suggests pubertal (central) activation.
- McCune-Albright syndrome = polyostotic fibrous dysplasia + café-au-lait spots (coast-of-Maine) + precocious puberty (autonomous ovarian cysts).
- hCG-secreting tumours (germ cell tumours, hepatoblastoma) cause PPP in boys because hCG mimics LH at Leydig cell receptors.
High Yield Summary — Diagnostic Approach
- First-line screening: Basal LH (most useful single test), FSH, sex steroids, bone age XR
- Basal LH > 0.2 mIU/L → CPP; < 0.2 → PPP or benign variant [2]
- GnRH stimulation test confirms CPP: peak LH pubertal, LH:FSH > 0.66 [7]
- MRI brain is mandatory for all boys with CPP and girls < 6y with CPP
- Bone age advanced in all PP except primary hypothyroidism (delayed) [15]
- For pubarche only: discriminate by growth rate — rapid growth + advanced BA → CAH/tumour; normal growth + mild BA → benign adrenarche [1]
- For thelarche only: discriminate by age and growth — birth–3y + normal BA → premature thelarche; rapid growth + advanced BA → McCune-Albright or exogenous oestrogen [1]
- PPP workup by source: adrenal (17-OHP, DHEAS, adrenal US), gonadal (pelvic/testicular US), hCG (β-hCG), thyroid (TFT)
- Biochemistry before imaging in endocrine workup [12]
- Testicular US in boys: bilateral ↑ = CPP, unilateral ↑ = tumour, prepubertal = PPP
High Yield Summary — Management
- CPP first-line: GnRH agonist (leuprolide IM Q4w) — works by overriding pulsatile GnRH → desensitisation of pituitary gonadotrophs → ↓LH/FSH → ↓sex steroids [2][7]
- PPP does NOT respond to GnRH agonist — must treat the underlying cause [7]
- PPP management: surgical removal ± chemoRT for tumour; drainage for ovarian cyst; glucocorticoid for CAH [2]
- GnRH antagonists are NOT FDA approved for paediatric CPP [7]
- GH may be added to GnRHa in patients with markedly advanced bone age and prediction of short stature [7]
- Benign variants: no intervention required [7]
- Secondary CPP can develop from prolonged PPP → add GnRH agonist
- Primary hypothyroidism-related PP reverses completely with levothyroxine
- Puberty resumes promptly when GnRHa is stopped at appropriate chronological age [7]
- Family-centred care: Psychosocial support, age-appropriate communication, safeguarding awareness
High Yield Summary — Complications
- Compromised final adult height is the cardinal complication — premature epiphyseal fusion from sex steroid exposure. Height benefit of treatment is greatest when onset < 6 years [1]
- Psychological complications — body image, social isolation, bullying, early menarche distress, risk of sexual exploitation — are the second major indication for treatment [1]
- GnRH agonist side effects are generally mild and reversible: initial flare (warn families), injection site reactions, transient ↓BMD (recovers), weight gain, persistence of pubic hair (adrenal androgens not suppressed — NOT a treatment failure)
- Fertility is NOT impaired by GnRH agonist treatment — this is a key parental reassurance point
- Metabolic complications: ↑risk of obesity, insulin resistance, PCOS (especially premature adrenarche + SGA + obesity)
- Complications of the underlying cause (CNS tumour, CAH, McCune-Albright, NF1, hepatoblastoma) may be more clinically significant than PP itself and require cause-specific surveillance
- Ketoconazole hepatotoxicity is the most important drug-specific complication to monitor in PPP treatment
- Secondary CPP can develop from prolonged PPP — a complication of the disease that changes the treatment strategy